{ "version": "2.2", "instance": { "iva-20251231x20f.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20251231", "dts": { "schema": { "local": [ "iva-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "iva-20251231_cal.xml" ] }, "definitionLink": { "local": [ "iva-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "iva-20251231_lab.xml" ] }, "presentationLink": { "local": [ "iva-20251231_pre.xml" ] }, "inline": { "local": [ "iva-20251231x20f.htm" ] } }, "keyStandard": 340, "keyCustom": 323, "axisStandard": 36, "axisCustom": 4, "memberStandard": 59, "memberCustom": 188, "hidden": { "total": 22, "http://www.inventivapharma.com/20251231": 14, "http://xbrl.sec.gov/dei/2025": 8 }, "contextCount": 1090, "entityCount": 1, "segmentCount": 260, "elementCount": 1212, "unitCount": 21, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2006, "http://xbrl.sec.gov/dei/2025": 46, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition", "longName": "995200100 - Statement - Consolidated statement of financial position", "shortName": "Consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:NoncurrentAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss", "longName": "995200200 - Statement - Consolidated statement of income (loss)", "shortName": "Consolidated statement of income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss", "longName": "995200300 - Statement - Consolidated statement of comprehensive income (loss)", "shortName": "Consolidated statement of comprehensive income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R5": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity", "longName": "995200400 - Statement - Consolidated statement of changes in shareholders' equity", "shortName": "Consolidated statement of changes in shareholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_m9JtuCaXIUSte9kSSpRmGQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_sdszi6Fpk0CbZZSW_jHWdQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows", "longName": "995200500 - Statement - Consolidated statement of cash flows", "shortName": "Consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical", "longName": "995200505 - Statement - Consolidated statement of cash flows (Parenthetical)", "shortName": "Consolidated statement of cash flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_iva_IfrsSaleOfStockAxis_iva_AtMarketOfferingMember_qzWVGsYUvUCm5Y08HC1aUQ", "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_iva_IfrsSaleOfStockAxis_iva_AtMarketOfferingMember_qzWVGsYUvUCm5Y08HC1aUQ", "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "995210101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "995210201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:BasisOfPreparationAndStatementOfComplianceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:BasisOfPreparationAndStatementOfComplianceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "995210301 - Disclosure - Accounting principles", "shortName": "Accounting principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssets", "longName": "995210401 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment", "longName": "995210501 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAsset", "longName": "995210601 - Disclosure - Deferred tax asset", "shortName": "Deferred tax asset", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethod", "longName": "995210701 - Disclosure - Investments accounted for using the equity method", "shortName": "Investments accounted for using the equity method", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets", "longName": "995210801 - Disclosure - Other non-current assets", "shortName": "Other non-current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureInventories", "longName": "995210901 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssets", "longName": "995211001 - Disclosure - Trade receivables, tax receivables and other current assets", "shortName": "Trade receivables, tax receivables and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlows", "longName": "995211101 - Disclosure - Cash and cash equivalents balance from the statement of cash flows", "shortName": "Cash and cash equivalents balance from the statement of cash flows", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquity", "longName": "995211201 - Disclosure - Shareholders' equity", "shortName": "Shareholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilities", "longName": "995211301 - Disclosure - Debt, Derivatives and Royalty certificates liabilities", "shortName": "Debt, Derivatives and Royalty certificates liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureProvisions", "longName": "995211401 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations", "longName": "995211501 - Disclosure - Provisions for retirement benefit obligations", "shortName": "Provisions for retirement benefit obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilities", "longName": "995211601 - Disclosure - Other current and non-current liabilities", "shortName": "Other current and non-current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilities", "longName": "995211701 - Disclosure - Trade payables and short-term contract liabilities", "shortName": "Trade payables and short-term contract liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities", "longName": "995211801 - Disclosure - Financial assets and liabilities", "shortName": "Financial assets and liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome", "longName": "995211901 - Disclosure - Revenues and other income", "shortName": "Revenues and other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpenses", "longName": "995212001 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpenses", "longName": "995212101 - Disclosure - Other operating income and expenses", "shortName": "Other operating income and expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses", "longName": "995212201 - Disclosure - Financial income and expenses", "shortName": "Financial income and expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethod", "longName": "995212301 - Disclosure - Share of net profit (loss) - Equity method", "shortName": "Share of net profit (loss) - Equity method", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTax", "longName": "995212401 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare", "longName": "995212501 - Disclosure - Basic and diluted loss per share", "shortName": "Basic and diluted loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivities", "longName": "995212601 - Disclosure - Commitments related to operational activities", "shortName": "Commitments related to operational activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions", "longName": "995212701 - Disclosure - Related-party transactions", "shortName": "Related-party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement", "longName": "995212801 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate", "longName": "995212901 - Disclosure - Events after the reporting date", "shortName": "Events after the reporting date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R37": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R38": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "99920302 - Disclosure - Accounting principles (Policies)", "shortName": "Accounting principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "99930203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "99930303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables", "longName": "99930403 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables", "longName": "99930503 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetTables", "longName": "99930603 - Disclosure - Deferred tax asset (Tables)", "shortName": "Deferred tax asset (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfDeferredTaxAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfDeferredTaxAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodTables", "longName": "99930703 - Disclosure - Investments accounted for using the equity method (Tables)", "shortName": "Investments accounted for using the equity method (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables", "longName": "99930803 - Disclosure - Other non-current assets (Tables)", "shortName": "Other non-current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureInventoriesTables", "longName": "99930903 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables", "longName": "99931003 - Disclosure - Trade receivables, tax receivables and other current assets (Tables)", "shortName": "Trade receivables, tax receivables and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsTables", "longName": "99931103 - Disclosure - Cash and cash equivalents balance from the statement of cash flows (Tables)", "shortName": "Cash and cash equivalents balance from the statement of cash flows (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables", "longName": "99931203 - Disclosure - Shareholders' equity (Tables)", "shortName": "Shareholders' equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables", "longName": "99931303 - Disclosure - Debt, Derivatives and Royalty certificates liabilities (Tables)", "shortName": "Debt, Derivatives and Royalty certificates liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsTables", "longName": "99931403 - Disclosure - Provisions (Tables)", "shortName": "Provisions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables", "longName": "99931503 - Disclosure - Provisions for retirement benefit obligations (Tables)", "shortName": "Provisions for retirement benefit obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesTables", "longName": "99931603 - Disclosure - Other current and non-current liabilities (Tables)", "shortName": "Other current and non-current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTables", "longName": "99931703 - Disclosure - Trade payables and short-term contract liabilities (Tables)", "shortName": "Trade payables and short-term contract liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables", "longName": "99931803 - Disclosure - Financial assets and liabilities (Tables)", "shortName": "Financial assets and liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables", "longName": "99931903 - Disclosure - Revenues and other income (Tables)", "shortName": "Revenues and other income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables", "longName": "99932003 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesTables", "longName": "99932103 - Disclosure - Other operating income and expenses - (Tables)", "shortName": "Other operating income and expenses - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables", "longName": "99932203 - Disclosure - Financial income and expenses (Tables)", "shortName": "Financial income and expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodTables", "longName": "99932303 - Disclosure - Share of net profit (loss) - Equity method (Tables)", "shortName": "Share of net profit (loss) - Equity method (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables", "longName": "99932403 - Disclosure - Income tax (Tables)", "shortName": "Income tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables", "longName": "99932503 - Disclosure - Basic and diluted loss per share (Tables)", "shortName": "Basic and diluted loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesTables", "longName": "99932603 - Disclosure - Commitments related to operational activities (Tables)", "shortName": "Commitments related to operational activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99932703 - Disclosure - Related-party transactions (Tables)", "shortName": "Related-party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables", "longName": "99932803 - Disclosure - Financial risk management (Tables)", "shortName": "Financial risk management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "longName": "99940101 - Disclosure - Company information (Details)", "shortName": "Company information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:RestructuringAndRelatedCostsPlannedWorkforceReduction", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_2_28_2025_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ClinicalDevelopmentProgramOfLanifibranorInJapanPhase1TrialMember_yc5iZF7CyU2TPO4iWJ6u1A", "name": "iva:NumberOfParticipantsInPhase1TrialOfLanifibranor", "unitRef": "Unit_Standard_item_olwYXpiO0kKdJTKBbI6czQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R68": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "longName": "99940102 - Disclosure - Company information - Equity financing (Details)", "shortName": "Company information - Equity financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_EUR_shares__Uw0alIDT0mMqmfvPIhcHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2025_To_10_31_2025_iva_IfrsSaleOfStockAxis_iva_AtMarketOfferingMember_n1qTF_oXQkW7UCla8wKmSg", "name": "iva:MaximumAggregateSalesProceedsFromIssuanceOfShares", "unitRef": "Unit_Standard_USD_1Jp-htNGJU-i0ktQBElS0Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R69": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "longName": "99940103 - Disclosure - Company information - Share-based payments and stock options (Details)", "shortName": "Company information - Share-based payments and stock options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_z8WeuPKH0Ea9y2Ppe3d62g", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_3ZQIy7JiAUe-174QnvNCbg", "name": "iva:NumberOfPlansOutstanding", "unitRef": "Unit_Standard_plan_yJELesDPxk6k4KdB6Aon4g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R70": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "longName": "99940104 - Disclosure - Company information - Significant events of 2025 (Details)", "shortName": "Company information - Significant events of 2025 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_uzIqPXI3F0Ws80BCRR9LkA", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_0UBVygB0NkWFhT4I-YyPRA", "name": "iva:WarrantsTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R71": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "longName": "99940105 - Disclosure - Company information - CTTQ and Share-based payments (Details)", "shortName": "Company information - CTTQ and Share-based payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_uzIqPXI3F0Ws80BCRR9LkA", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_11_2024_To_10_11_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_hoJvqyCmCkKoLUUKfao_tw", "name": "iva:MinimumGrossFundingToBeRaised", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R72": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "longName": "99940106 - Disclosure - Company information - Company to present the results of LEGEND Phase (Details)", "shortName": "Company information - Company to present the results of LEGEND Phase (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_6_13_2023_To_6_13_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_K8K-98QOKk66tqdxcVrniw", "name": "iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_13_2023_To_6_13_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_K8K-98QOKk66tqdxcVrniw", "name": "iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "longName": "99940107 - Disclosure - Company information - Licensing agreement with Hepalys (Details)", "shortName": "Company information - Licensing agreement with Hepalys (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_9_26_2023_srt_StatementGeographicalAxis_country_KR_qTpu_keOTUSg-wOa71OSeQ", "name": "iva:OptionToAcquireSharesInCompanyPercentage", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_26_2023_srt_StatementGeographicalAxis_country_KR_qTpu_keOTUSg-wOa71OSeQ", "name": "iva:OptionToAcquireSharesInCompanyPercentage", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "longName": "99940108 - Disclosure - Company information - Ordinary shares of Hepalys (Details)", "shortName": "Company information - Ordinary shares of Hepalys (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_29_2023_To_9_29_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_G53mqr5ZzkK5aY8pRpkslQ", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_USD_1Jp-htNGJU-i0ktQBElS0Q", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R75": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "99940201 - Disclosure - Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_fvQ2IMPZC0WBwT2hVUYvow", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_fvQ2IMPZC0WBwT2hVUYvow", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "99940202 - Disclosure - Basis of preparation and statement of compliance - Foreign exchange rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign exchange rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_aowdapjXCE-IIrEx7o0nNw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_aowdapjXCE-IIrEx7o0nNw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "longName": "99940301 - Disclosure - Accounting principles - Property, plant and equipment (Details)", "shortName": "Accounting principles - Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IlB0G017f0iJdtKTb-hQGQ", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_IlB0G017f0iJdtKTb-hQGQ", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "longName": "99940302 - Disclosure - Accounting principles - Derivatives (Details)", "shortName": "Accounting principles - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_14_2024_To_12_31_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_qPlGL2-4mUeLkaN0PY-qZg", "name": "iva:IncreaseDecreaseInFairValueOfDerivativeFinancialLiability", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R79": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "longName": "99940303 - Disclosure - Accounting principles - Royalty certificates liabilities (Details)", "shortName": "Accounting principles - Royalty certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificates2023Member_NcemswnTh0Wa30CjwH1CCg", "name": "iva:PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "99940304 - Disclosure - Accounting principles - Fair value measurement (Details)", "shortName": "Accounting principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_aFU9InSb1EmZ47P4BbZPpQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R81": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails", "longName": "99940305 - Disclosure - Accounting principles - Foreign currency transactions and Segment information (Details)", "shortName": "Accounting principles - Foreign currency transactions and Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AmountOfExpensesDenominatedInForeignCurrency", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AmountOfExpensesDenominatedInForeignCurrency", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "longName": "99940306 - Disclosure - Accounting principles - Geographical split (Details)", "shortName": "Accounting principles - Geographical split (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_GeographicalAreasAxis_country_FR_Ud0RYNRZ-0yPRTJj-CZneg", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R83": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "99940307 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R84": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "longName": "99940401 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IncreasesInIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R85": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "longName": "99940501 - Disclosure - Property, plant and equipment (Details)", "shortName": "Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IncreasesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R86": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "99940502 - Disclosure - Property, plant and equipment - Additional Information (Details)", "shortName": "Property, plant and equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:DecreasesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_9AMn3qEh70GicU4Ew4Jmew", "name": "ifrs-full:IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R87": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "longName": "99940601 - Disclosure - Deferred tax asset (Details)", "shortName": "Deferred tax asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R88": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "longName": "99940602 - Disclosure - Deferred tax asset - Additional Information (Details)", "shortName": "Deferred tax asset - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R89": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "longName": "99940701 - Disclosure - Investments accounted for using the equity method (Details)", "shortName": "Investments accounted for using the equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "Duration_9_29_2023_To_9_29_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_G53mqr5ZzkK5aY8pRpkslQ", "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R90": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "longName": "99940702 - Disclosure - Investments accounted for using the equity method - Investment in Hepalys accounted for using equity method of accounting (Details)", "shortName": "Investments accounted for using the equity method - Investment in Hepalys accounted for using equity method of accounting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_zL-ADj-FFka65Hc4AlITSw", "name": "iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R91": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "longName": "99940801 - Disclosure - Other non-current assets (Details)", "shortName": "Other non-current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_3jyomIIaPE2GGAXv_EoYlQ", "name": "iva:NonCurrentSecurityDeposits", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R92": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "longName": "99940802 - Disclosure - Other non-current assets - Additional information (Details)", "shortName": "Other non-current assets - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "iva:NonCurrentAdvancesToSuppliers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositForwardContractMember_2NCopCk9wk-79DwtGYaoUw", "name": "iva:LongTermDepositsClosed", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R93": { "role": "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "longName": "99940901 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "As_Of_12_31_2023_3jyomIIaPE2GGAXv_EoYlQ", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_oN-L_hVwiUWifOwbHpb8eQ", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R94": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "longName": "99941001 - Disclosure - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "shortName": "Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:CurrentTradeReceivablesAveragePaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R95": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "longName": "99941002 - Disclosure - Trade receivables, tax receivables and other current assets - Other Current Assets and Receivables (Details)", "shortName": "Trade receivables, tax receivables and other current assets - Other Current Assets and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "longName": "99941003 - Disclosure - Trade receivables, tax receivables and other current assets - Additional Information (Details)", "shortName": "Trade receivables, tax receivables and other current assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "iva:CirReceivable", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "iva:CirReceivable", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails", "longName": "99941101 - Disclosure - Cash and cash equivalents balance from the statement of cash flows (Details)", "shortName": "Cash and cash equivalents balance from the statement of cash flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "longName": "99941102 - Disclosure - Cash and cash equivalents balance from the statement of cash flows - Additional Information (Details)", "shortName": "Cash and cash equivalents balance from the statement of cash flows - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R99": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "longName": "99941201 - Disclosure - Shareholders' equity - Share capital (Details)", "shortName": "Shareholders' equity - Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R100": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "longName": "99941202 - Disclosure - Shareholders' equity - Changes in share capital (Details)", "shortName": "Shareholders' equity - Changes in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_28_2025_To_4_28_2025_iva_IfrsSaleOfStockAxis_iva_FinancingArrangementInThreeTranches2024TrancheIMember_cnEf_uY48EuxQZeZo67DOQ", "name": "iva:NumberOfWarrantsExercisedDuringPeriodShares", "unitRef": "Unit_Standard_shares_xD58S0zum0G2_Pk5BhaJVA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R101": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "longName": "99941203 - Disclosure - Shareholders' equity - Liquidity agreement (Details)", "shortName": "Shareholders' equity - Liquidity agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "Duration_5_22_2025_To_5_22_2025_iva_IfrsSaleOfStockAxis_iva_LiquidityAgreementWithKeplerCheuvreuxMember_1Ap7KateHkyeNZNfzGmhWw", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_22_2025_To_5_22_2025_iva_IfrsSaleOfStockAxis_iva_LiquidityAgreementWithKeplerCheuvreuxMember_1Ap7KateHkyeNZNfzGmhWw", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "longName": "99941204 - Disclosure - Shareholders' equity - Share warrants plans (Details)", "shortName": "Shareholders' equity - Share warrants plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_OT2bMRzDk0mirUj04TQ-yg", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares__Uw0alIDT0mMqmfvPIhcHw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_OT2bMRzDk0mirUj04TQ-yg", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares__Uw0alIDT0mMqmfvPIhcHw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "longName": "99941205 - Disclosure - Shareholders' equity - Characteristics of BSPCE plans (Details)", "shortName": "Shareholders' equity - Characteristics of BSPCE plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_z8WeuPKH0Ea9y2Ppe3d62g", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_16_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_QXFajx2S0kerLPSjuxGlQA", "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "Unit_Standard_shares_xD58S0zum0G2_Pk5BhaJVA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R104": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "longName": "99941206 - Disclosure - Shareholders' equity - Characteristics of BSA plans (Details)", "shortName": "Shareholders' equity - Characteristics of BSA plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_z8WeuPKH0Ea9y2Ppe3d62g", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_R3zZKBDAa02cynGiKmNWkQ", "name": "iva:NumberOfPlansOutstanding", "unitRef": "Unit_Standard_plan_yJELesDPxk6k4KdB6Aon4g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R105": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "longName": "99941207 - Disclosure - Shareholders' equity - Movements in BSPCE and BSA share warrants (Details)", "shortName": "Shareholders' equity - Movements in BSPCE and BSA share warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "As_Of_12_31_2023_3jyomIIaPE2GGAXv_EoYlQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_QDB3_HvFT0KV1xEz5o75Tg", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R106": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "longName": "99941208 - Disclosure - Shareholders' equity - Bonus share award plans (Details)", "shortName": "Shareholders' equity - Bonus share award plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_z8WeuPKH0Ea9y2Ppe3d62g", "name": "ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_AgaAndBsaPlansMember_0Fw9MGzIzk6nR6WRq_Hd8Q", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R107": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "longName": "99941209 - Disclosure - Shareholders' equity - Movements in AGA (Details)", "shortName": "Shareholders' equity - Movements in AGA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "As_Of_12_31_2023_3jyomIIaPE2GGAXv_EoYlQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_Y8O1uNGhi02Dm1FJmRxSDQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R108": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "longName": "99941210 - Disclosure - Shareholders' equity - Performance unit plans (Details)", "shortName": "Shareholders' equity - Performance unit plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "As_Of_12_31_2023_3jyomIIaPE2GGAXv_EoYlQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_d1YTH_wSWUSENmLV5hqg5A", "name": "iva:ReferencePricePerUnit", "unitRef": "Unit_Divide_EUR_shares__Uw0alIDT0mMqmfvPIhcHw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R109": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "longName": "99941211 - Disclosure - Shareholders' equity - Stock Option plans (Details)", "shortName": "Shareholders' equity - Stock Option plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_Options_bnWel1AXNkS16QlY6ZZvfw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_Options_bnWel1AXNkS16QlY6ZZvfw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R110": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "longName": "99941301 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Financial debt (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Financial debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ifrs-full_ShorttermBorrowingsMember_kAYnF7Xc-k6WI4Wjg8DSCw", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R111": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "longName": "99941302 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Maturity of long term debt and of short term borrowings and debt (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Maturity of long term debt and of short term borrowings and debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_LCFCoZSV1k6ogK7izXRFAw", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R112": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails", "longName": "99941303 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Movements in the period break down (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Movements in the period break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "iva:DebtFinancial", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IncreaseInBorrowingsThroughNewLeases", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R113": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "longName": "99941304 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Movements (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Movements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "iva:DebtFinancial", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AdditionsToFinancialDebt", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R114": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "99941305 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_uzIqPXI3F0Ws80BCRR9LkA", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_WzccotytQUiQLaUviJ9kTw", "name": "iva:NumberOfLoanAgreements", "unitRef": "Unit_Standard_loan_-kI7QFGSnkezME17sICY6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R115": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "99941306 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_QPH4GeeywkO9NVrhMp6qmA", "name": "iva:NotionalAmountPerTranche", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R116": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "longName": "99941307 - Disclosure - Debt, Derivatives and Royalty certificates liabilities- Derivatives (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities- Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_z8WeuPKH0Ea9y2Ppe3d62g", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_EquityInstruments_djN6i3OmHk-FpeSH_TLc-A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_uFgspKVEzEuP1wvnYKsaOA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares__Uw0alIDT0mMqmfvPIhcHw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R117": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "longName": "99941308 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Short-term derivatives (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Short-term derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_7_2025_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_T2NewSharesAndT2BsasCallOptionsMember_NSjXOLcnzUiQo3FC1QP_vQ", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R118": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "longName": "99941309 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Lease liabilities (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:LeaseLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IncreaseDecreaseInLeaseLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R119": { "role": "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "longName": "99941310 - Disclosure - Debt, Derivatives and Royalty certificates liabilities - Royalty Certificates liabilities (Details)", "shortName": "Debt, Derivatives and Royalty certificates liabilities - Royalty Certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_s1NWSgYe0EOd1StbsjSOrw", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R120": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "longName": "99941401 - Disclosure - Provisions (Details)", "shortName": "Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AdditionalProvisionsOtherShortTermProvisions", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:AdditionalProvisionsOtherShortTermProvisions", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R121": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails", "longName": "99941501 - Disclosure - Provisions for retirement benefit obligations - Principal actuarial assumptions (Details)", "shortName": "Provisions for retirement benefit obligations - Principal actuarial assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R122": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "longName": "99941502 - Disclosure - Provisions for retirement benefit obligations - Net provision (Details)", "shortName": "Provisions for retirement benefit obligations - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R123": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "longName": "99941503 - Disclosure - Provisions for retirement benefit obligations - Changes in the net provision (Details)", "shortName": "Provisions for retirement benefit obligations - Changes in the net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_uzIqPXI3F0Ws80BCRR9LkA", "name": "ifrs-full:IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R124": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails", "longName": "99941504 - Disclosure - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "shortName": "Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R125": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "longName": "99941505 - Disclosure - Provisions for retirement benefit obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "shortName": "Provisions for retirement benefit obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R126": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails", "longName": "99941506 - Disclosure - Provisions for retirement benefit obligations - Sensitivity analysis (Details)", "shortName": "Provisions for retirement benefit obligations - Sensitivity analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ActuarialAssumptionsAxis_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_l6aVL864JkWB0t_huLbHEg", "name": "iva:PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R127": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails", "longName": "99941601 - Disclosure - Other current and non-current liabilities (Details)", "shortName": "Other current and non-current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R128": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "longName": "99941602 - Disclosure - Other current and non-current liabilities - Additional information (Details)", "shortName": "Other current and non-current liabilities - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:OtherNoncurrentLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:IfrsIncreaseDecreaseInOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R129": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails", "longName": "99941701 - Disclosure - Trade payables and short-term contract liabilities (Details)", "shortName": "Trade payables and short-term contract liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R130": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails", "longName": "99941702 - Disclosure - Trade payables and short-term contract liabilities - Trade payables break down (Details)", "shortName": "Trade payables and short-term contract liabilities - Trade payables break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:AccrualsClassifiedAsCurrent", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R131": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "longName": "99941801 - Disclosure - Financial assets and liabilities (Details)", "shortName": "Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R132": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "longName": "99941901 - Disclosure - Revenues and other income (Details)", "shortName": "Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R133": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "longName": "99941902 - Disclosure - Revenues and other income - Narrative (Details)", "shortName": "Revenues and other income - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:IncreaseDecreaseInOtherMiscellaneousIncome", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R134": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "longName": "99942001 - Disclosure - Operating expenses (Details)", "shortName": "Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:Studies", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:Studies", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R135": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "longName": "99942002 - Disclosure - Operating expenses - Personnel costs and headcount (Details)", "shortName": "Operating expenses - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_RfQo8sYhB0Ov2UB8jgnRrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_Vs0po7GbNkCZSKgo8f62rg", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_RfQo8sYhB0Ov2UB8jgnRrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R136": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "longName": "99942003 - Disclosure - Operating expenses - Additional Information (Details)", "shortName": "Operating expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_II6ZW-anjEiae7aFcnYPYA", "name": "iva:WithHoldingTaxRate", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_II6ZW-anjEiae7aFcnYPYA", "name": "iva:WithHoldingTaxRate", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R137": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "longName": "99942101 - Disclosure - Other operating income and expenses (Details)", "shortName": "Other operating income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:ReversalOfProvisionsForInventory", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "iva:ReversalOfProvisionsForInventory", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R138": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "longName": "99942102 - Disclosure - Other operating income and expenses - Additional Information (Details)", "shortName": "Other operating income and expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ExpenseOfRestructuringActivities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_uzIqPXI3F0Ws80BCRR9LkA", "name": "iva:IncreaseDecreaseInOtherOperatingExpense", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R139": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "longName": "99942201 - Disclosure - Financial income and expenses (Details)", "shortName": "Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R140": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "longName": "99942301 - Disclosure - Share of net profit (loss) - Equity method (Details)", "shortName": "Share of net profit (loss) - Equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_he6ir6_3xkmRXyCgM92gZQ", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R141": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "longName": "99942401 - Disclosure - Income tax (Details)", "shortName": "Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R142": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "longName": "99942501 - Disclosure - Basic and diluted loss per share (Details)", "shortName": "Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_FO2WVGohuUuaM6HxLCLN3Q", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R143": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "longName": "99942601 - Disclosure - Commitments related to operational activities - Commitments given and received (Details)", "shortName": "Commitments related to operational activities - Commitments given and received (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "iva:AgreementsConcerningProvisionOfFacilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R144": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "longName": "99942602 - Disclosure - Commitments related to operational activities (Details)", "shortName": "Commitments related to operational activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_14_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesBvMember_0vm1fdN690-j-Jd0r6IktQ", "name": "iva:CommitmentsAmountPayableForServicesReceivedUnderContract", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R145": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99942701 - Disclosure - Related-party transactions (Details)", "shortName": "Related-party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "As_Of_12_20_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_PierreBroquaMember_2_vaJ_aiYUCxsIvZt_3baQ", "name": "iva:AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_20_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_PierreBroquaMember_2_vaJ_aiYUCxsIvZt_3baQ", "name": "iva:AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R146": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "longName": "99942702 - Disclosure - Related-party transactions - Summary of transactions with key management personnel (Details)", "shortName": "Related-party transactions - Summary of transactions with key management personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_g9Nx9C4fjE6-AiVg3zAHXA", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_g9Nx9C4fjE6-AiVg3zAHXA", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } }, "R147": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "longName": "99942801 - Disclosure - Financial risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "shortName": "Financial risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_1hs7P2zylk2h_34SFv68-A", "name": "iva:PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R148": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails", "longName": "99942802 - Disclosure - Financial risk management - Liquidity risk (Details)", "shortName": "Financial risk management - Liquidity risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "As_Of_12_31_2025_tVWwOCC-1Ey4lTXEOMeN2g", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_AccruedInterestOnBorrowingsMember_nKkXXX3QhEay7dl-YRa21Q", "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "unitRef": "Unit_Standard_EUR_AW2SvCGPDEWffFXGUTqtyg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "unique": true } }, "R149": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails", "longName": "99942803 - Disclosure - Financial risk management - Inflation risk (Details)", "shortName": "Financial risk management - Inflation risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfRisksAxis_iva_InflationRiskMember_TMoF1f5OdU2L9_A7foTB_A", "name": "iva:ExperiencedInflationDuringPeriod", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfRisksAxis_iva_InflationRiskMember_TMoF1f5OdU2L9_A7foTB_A", "name": "iva:ExperiencedInflationDuringPeriod", "unitRef": "Unit_Standard_pure_qKyuyeAU3UOOfIKaYxXTyg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20251231x20f.htm", "first": true, "unique": true } } }, "tag": { "iva_AbsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AbsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents ABSA warrants.", "label": "ABSA warrants [Member]", "terseLabel": "ABSA warrants" } } }, "auth_ref": [] }, "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting principles" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Loss before tax" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r3", "r4", "r216", "r217" ] }, "iva_AccrualInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccrualInterestsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to accrual interest.", "label": "Accrual Interests [Member]", "verboseLabel": "Accrual Interests" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r542" ] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income", "terseLabel": "Current accrued income" } } }, "auth_ref": [] }, "iva_AccruedInterestOnBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccruedInterestOnBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents accrued interest on borrowings.", "label": "Accrued interest on borrowings [Member]", "terseLabel": "Accrued interest payable on loans" } } }, "auth_ref": [] }, "iva_AccruedInterestPayableOnLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccruedInterestPayableOnLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued interest payable on loans.", "label": "Accrued interest payable on loans [Member]", "verboseLabel": "Accrued interest payable on loans" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employee-related taxes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization and impairment", "verboseLabel": "Depreciation and impairment" } } }, "auth_ref": [ "r11", "r15", "r55", "r62", "r65", "r223", "r246", "r252", "r255" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated impairment [member]", "terseLabel": "Inventories write-down" } } }, "auth_ref": [ "r142", "r151", "r274", "r366", "r508", "r518", "r519", "r520" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r512" ] }, "iva_ActuarialAssumptionOfDiscountRatesAt2.95PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt2.95PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 2.95% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 2.95 Percent [Member]", "terseLabel": "Discount rate at 2.95%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.15PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.15PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.15% used as actuarial assumptions", "label": "Actuarial Assumption Of Discount Rates At 3.15 Percent [Member]", "terseLabel": "Discount rate at 3.15%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.20PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.20PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.20% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 3.20 Percent [Member]", "terseLabel": "Discount rate at 3.20%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.40PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.40PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.40% used as actuarial assumptions", "label": "Actuarial Assumption Of Discount Rates At 3.40 Percent [Member]", "terseLabel": "Discount rate at 3.40%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.45PercentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.45PercentOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.45% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 3.45 Percent one [Member]", "terseLabel": "Discount rate at 3.45%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.65PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.65PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.65% used as actuarial assumptions", "label": "Actuarial Assumption Of Discount Rates At 3.65 Percent [Member]", "terseLabel": "Discount rate at 3.65%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.70PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.70PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.70% used as actuarial assumptions.", "label": "Discount rate at 3.70%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.95PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.95PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.95% used as actuarial assumptions.", "label": "Discount rate at 3.95%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt4.20PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesAt4.20PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 4.20% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 4.20 Percent [Member]", "terseLabel": "Discount rate at 4.20%" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates [member]", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r513" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Salary growth rate" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r512" ] }, "iva_ActuarialAssumptionOfRatesOfPayrollTaxes": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ActuarialAssumptionOfRatesOfPayrollTaxes", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The expected rate of payroll taxes used as a significant actuarial assumption to determine the present value of a defined benefit obligation.", "label": "Actuarial Assumption Of Rates Of Payroll Taxes", "terseLabel": "Payroll taxes" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of retirement age", "terseLabel": "Retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r512" ] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21" ] }, "ifrs-full_ActuarialAssumptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [domain]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r21" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans", "terseLabel": "Demographic changes" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]" } } }, "auth_ref": [ "r510" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans", "terseLabel": "Changes in actuarial assumptions" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]" } } }, "auth_ref": [ "r510" ] }, "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from experience adjustments, net of tax, defined benefit plans", "terseLabel": "Difference between expected and actual performance" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments]" } } }, "auth_ref": [ "r510" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r443" ] }, "iva_AdditionalProceedsReceivableUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdditionalProceedsReceivableUponExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional proceeds receivable upon exercise of warrants.", "label": "Additional Proceeds Receivable Upon Exercise Of Warrants", "terseLabel": "Additional proceeds receivable upon exercise of warrants" } } }, "auth_ref": [] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Additional provisions, other provisions", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r52", "r243" ] }, "iva_AdditionalProvisionsOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdditionalProvisionsOtherShortTermProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional other provisions made, classified as short-term.", "label": "Additional Provisions, Other Short-Term Provisions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "verboseLabel": "Intangible assets acquired" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r56", "r247" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets", "terseLabel": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r509" ] }, "iva_AdditionsToFinancialDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdditionsToFinancialDebt", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Additions to financial debt", "label": "Additions to financial debt", "terseLabel": "Additions" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r456" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r456" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r456" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r456" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r45" ] }, "iva_AdjustmentToWarrantSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentToWarrantSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to warrant subscription price.", "label": "Adjustment to warrant subscription price" } } }, "auth_ref": [] }, "iva_AdjustmentsForCostOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentsForCostOfDebt", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for cost of debt.", "label": "Adjustments for cost of debt", "negatedLabel": "Cost of debt" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventories" } } }, "auth_ref": [ "r523" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "verboseLabel": "Variation of prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r525" ] }, "iva_AdjustmentsForDecreaseIncreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentsForDecreaseIncreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in short-term deposit accounts to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Decrease (Increase) in Short-Term Deposit Accounts", "terseLabel": "Increase in short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r525" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } } }, "auth_ref": [ "r524" ] }, "iva_AdjustmentsForGainsLossesOnDisposalOfTangibleAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentsForGainsLossesOnDisposalOfTangibleAndIntangibleAssets", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss) on disposals of tangible and intangible assets to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Gains (Losses)On Disposal Of Tangible and Intangible Assets", "negatedLabel": "Net book value of tangible and intangible assets disposed" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r525" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } } }, "auth_ref": [ "r524" ] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of net profit of associates and joint ventures accounted for using the equity method" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } } }, "auth_ref": [ "r354", "r524" ] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdrMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Adr [member]", "terseLabel": "ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r396" ] }, "iva_AdvancePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AdvancePaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payment.", "label": "Advance payment", "terseLabel": "Advance payment" } } }, "auth_ref": [] }, "iva_Aga2021Aga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga2021Aga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2021 & AGA 2021 bis.", "label": "AGA 2021 & AGA 2021 bis [Member]", "terseLabel": "AGA 2021 & AGA 2021 bis", "verboseLabel": "AGA 2021 & AGA 2021 BIS" } } }, "auth_ref": [] }, "iva_Aga2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2022 Plan).", "label": "AGA 2022 [Member]", "terseLabel": "AGA 2022" } } }, "auth_ref": [] }, "iva_Aga20231Ags20241AndAga20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20231Ags20241AndAga20251Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2023-1, AGA 2024-1 and AGA 2025-1.", "label": "AGA 20231, AGS 20241 And AGA 20251 [Member]", "terseLabel": "AGA 2023-1, AGS 2024-1 And AGA 2025-1" } } }, "auth_ref": [] }, "iva_Aga20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-2).", "label": "AGA 2023-1 [Member]", "terseLabel": "AGA 2023-1" } } }, "auth_ref": [] }, "iva_Aga20241Aga20242AndAga20243Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20241Aga20242AndAga20243Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-1, AGA- 2024-2 and AGA 2024-3.", "label": "AGA 2024-1, AGA- 2024-2 and AGA 2024-3 [Member]", "terseLabel": "AGA 2024-1, AGA- 2024-2 and AGA 2024-3" } } }, "auth_ref": [] }, "iva_Aga20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20241Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-1.", "label": "AGA 2024-1 [Member]", "terseLabel": "AGA 2024-1", "verboseLabel": "AGA 2024-1 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20242Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-2.", "label": "AGA 2024-2 [Member]", "terseLabel": "AGA 2024-2", "verboseLabel": "AGA 2024-2 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20243Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20243Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-3.", "label": "AGA 2024-3 [Member]", "terseLabel": "AGA 2024-3", "verboseLabel": "AGA 2024-3 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20244Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20244Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-4.", "label": "AGA 2024-4 [Member]", "terseLabel": "AGA 2024-4", "verboseLabel": "AGA 2024-4 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20251Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-1.", "label": "AGA 2025-1 [Member]", "terseLabel": "AGA 2025-1", "verboseLabel": "AGA 2025-1 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20251Tr4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20251Tr4Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-1 (Tr4).", "label": "AGA 2025-1 (Tr4) [Member]", "terseLabel": "AGA 2025-1 (Tr4)" } } }, "auth_ref": [] }, "iva_Aga20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20252Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-2.", "label": "AGA 2025-2 [Member]", "terseLabel": "AGA 2025-2" } } }, "auth_ref": [] }, "iva_Aga20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20253Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-3.", "label": "AGA 2025-3 [Member]", "terseLabel": "AGA 2025-3" } } }, "auth_ref": [] }, "iva_Aga20254Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20254Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-4.", "label": "AGA 2025-4 [Member]", "terseLabel": "AGA 2025-4" } } }, "auth_ref": [] }, "iva_Aga20255Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Aga20255Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-5.", "label": "AGA 2025-5 [Member]", "terseLabel": "AGA 2025-5" } } }, "auth_ref": [] }, "iva_AgaAndBsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AgaAndBsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents AGA and BSA share-based payment plans.", "label": "AGA and BSA plans [member]", "terseLabel": "AGA and BSA plans" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares or Warrants Of The Company", "terseLabel": "Structured Financing amount", "verboseLabel": "Structured equity financing amount" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r501" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r414", "r425", "r435", "r468" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r417", "r428", "r438", "r471" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r502" ] }, "iva_AgreementWithContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AgreementWithContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for agreement with clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products.", "label": "Agreement With Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "iva_AgreementsConcerningProvisionOfFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AgreementsConcerningProvisionOfFacilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of agreements concerning provision of facilities.", "label": "Agreements concerning the provision of facilities", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r456" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r463" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r418", "r429", "r439", "r463", "r472", "r476", "r484" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r482" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares, each representing one ordinary share.", "label": "American Depositary Shares, each representing one ordinary share" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountInvoicedToCounterparty", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty.", "label": "Amount Invoiced To Counterparty", "terseLabel": "Milestone payment received", "verboseLabel": "Amount invoiced to counterparty" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountInvoicedToCounterpartyForAdditionalPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for additional payment.", "label": "Amount Invoiced To Counterparty For Additional Payment", "terseLabel": "Amount invoiced to counterparty for additional payment" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountInvoicedToCounterpartyForInitialPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for initial payment.", "label": "Amount Invoiced To Counterparty For Initial Payment", "terseLabel": "Amount invoiced to counterparty for milestone payment" } } }, "auth_ref": [] }, "iva_AmountOfExpensesDenominatedInForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountOfExpensesDenominatedInForeignCurrency", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenses denominated in foreign currency.", "label": "Amount of expenses denominated in foreign currency", "terseLabel": "Amount of expenses in a foreign currency" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRights", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights.", "label": "Amount payable to related parties for transfer of patent intellectual property rights" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsConditionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsConditionalAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights, conditional amount", "label": "Amount payable to related parties for transfer of patent intellectual property rights, conditional amount", "terseLabel": "Amount payable to related parties of patent intellectual property, conditional amount" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights, unconditional amount", "label": "Amount payable to related parties for transfer of patent intellectual property rights, unconditional amount", "terseLabel": "Amount payable to related parties for patent intellectual property rights unconditional amount" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartyForTransferOfKnowHow": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AmountPayableToRelatedPartyForTransferOfKnowHow", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related party for transfer of know-how.", "label": "Amount payable to related party for transfer of know-how", "terseLabel": "Amount payable to related party" } } }, "auth_ref": [] }, "iva_AndrewObenshainMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AndrewObenshainMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Andrew Obenshain.", "label": "Andrew Obenshain [Member]", "terseLabel": "Andrew Obenshain" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Applicable tax rate", "verboseLabel": "Theoretical tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r4", "r217" ] }, "iva_ApproximateNumberOfSharesExpectedToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ApproximateNumberOfSharesExpectedToBeIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Approximate number of shares expected to be issued", "label": "Approximate number of shares expected to be issued", "terseLabel": "Number of instruments" } } }, "auth_ref": [] }, "iva_ApproximateNumberOfWarrantsExpectedToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ApproximateNumberOfWarrantsExpectedToBeIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Approximate number of warrants expected to be issued", "label": "Approximate number of warrants expected to be issued", "terseLabel": "Number of instruments" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r103", "r104", "r106", "r174", "r178", "r282", "r283", "r311" ] }, "iva_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "At Market Offering [Member]", "terseLabel": "ATM" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r532", "r535" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r532", "r535" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r397", "r398", "r421" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r397", "r398", "r421" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r397", "r398", "r421" ] }, "iva_August2023ShareIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "August2023ShareIssuanceMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents august 2023.", "label": "August 2023 Share Issuance [Member]", "terseLabel": "August 2023" } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r4", "r217" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r535" ] }, "iva_AverageLifeOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "AverageLifeOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The average life of other equity instruments granted.", "label": "Average Life, Other Equity Instruments Granted", "terseLabel": "Average life (years)" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r479" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r475" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r475" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r475" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r475" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r475" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r475" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r478" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r477" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r476" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r476" ] }, "iva_BankBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BankBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bank borrowings.", "label": "Bank Borrowings [Member]", "terseLabel": "Total Bank Borrowings", "verboseLabel": "Bank Borrowings" } } }, "auth_ref": [] }, "iva_BasedOnMarketConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BasedOnMarketConditionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to based on market condition.", "label": "Based On Market Condition [Member]", "terseLabel": "Based on Market Condition" } } }, "auth_ref": [] }, "iva_BasedOnNonMarketConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BasedOnNonMarketConditionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to based on non-market condition.", "label": "Based On Non-Market Condition [Member]", "terseLabel": "Based on Non-Market Condition" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r43", "r44" ] }, "iva_BasisOfPreparationAndStatementOfComplianceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BasisOfPreparationAndStatementOfComplianceTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for basis of preparation and statement of compliance.", "label": "Basis of preparation and statement of compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "iva_BeiEmpruntPart12022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BeiEmpruntPart12022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to BEI EMPRUNT PART 1 2022.", "label": "BEI EMPRUNT PART 1 2022 [Member]", "terseLabel": "BEI EMPRUNT PART 1 2022" } } }, "auth_ref": [] }, "iva_BenefitObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BenefitObligationPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of benefit obligation percentage.", "label": "Benefit Obligation Percentage" } } }, "auth_ref": [] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]", "terseLabel": "Bonus share award plans (AGA)" } } }, "auth_ref": [] }, "iva_BonusSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BonusSharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The member represents Bonus shares.", "label": "Bonus shares [Member]", "terseLabel": "Bonus shares" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r535" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "terseLabel": "Borrowings", "verboseLabel": "Debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r539" ] }, "iva_BorrowingsActualizationRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BorrowingsActualizationRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The actualization interest rate on borrowings.", "label": "Borrowings, Actualization Rate", "terseLabel": "Actualization rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r530" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r530" ] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate", "terseLabel": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r530" ] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r73", "r107", "r122", "r136", "r207", "r359", "r361", "r530" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan", "terseLabel": "BSA 2017", "verboseLabel": "BSA - Plan 2017" } } }, "auth_ref": [] }, "iva_Bsa20181PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa20181PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018-1 plan.", "label": "BSA - 2018-1 Plan [Member]", "terseLabel": "BSA 2018-1" } } }, "auth_ref": [] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan", "terseLabel": "BSA - Plan 2018" } } }, "auth_ref": [] }, "iva_Bsa2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa2019PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2019 plan.", "label": "BSA - 2019 plan", "terseLabel": "BSA 2019" } } }, "auth_ref": [] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023-1" } } }, "auth_ref": [] }, "iva_Bsa20232ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bsa20232ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-2 share warrants plan.", "label": "BSA 2023-2 Share Warrant Plan [Member]", "verboseLabel": "BSA 2023-2" } } }, "auth_ref": [] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans", "terseLabel": "BSA Plans" } } }, "auth_ref": [] }, "iva_BsaShareWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BsaShareWarrantMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrant.", "label": "BSA Share warrant [Member]", "terseLabel": "BSA Share warrant" } } }, "auth_ref": [] }, "iva_BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants", "terseLabel": "BSA share warrants" } } }, "auth_ref": [] }, "iva_Bspce2013PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bspce2013PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2013 plan.", "label": "BSPCE - 2013 Plan", "terseLabel": "BSPCE - Plan 2013" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021", "terseLabel": "BSPCE 2021", "verboseLabel": "BSPCE - Plan 2021" } } }, "auth_ref": [] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants" } } }, "auth_ref": [] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "iva_BspceShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "BspceShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE share warrants.", "label": "BSPCE Share Warrants [Member]", "terseLabel": "BSPCE Share Warrants" } } }, "auth_ref": [] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Buildings [member]", "terseLabel": "Buildings" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "terseLabel": "Business Contact", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r398", "r421" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CN", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Commitments related to operational activities" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Capital reserve", "terseLabel": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r539" ] }, "iva_CapitalSurplusOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CapitalSurplusOthers", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing the capital surplus classified as others.", "label": "Capital Surplus, Others", "terseLabel": "Capital surplus-others" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r11", "r13", "r55", "r57", "r61", "r62", "r63", "r64", "r65", "r142", "r151", "r152", "r223", "r225", "r246", "r248", "r251", "r252", "r253", "r254", "r255", "r265", "r274", "r275" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r13", "r57", "r61", "r63", "r64", "r142", "r151", "r152", "r225", "r248", "r251", "r253", "r254", "r265", "r274", "r275" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r526" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r74", "r96", "r208", "r307" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents balance from the statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents if different from statement of financial position", "totalLabel": "Cash and cash equivalents balance from the statement of cash flows" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r526" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r521" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "terseLabel": "Net cash generated by financing activities", "totalLabel": "Net cash flows provided by financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r66", "r76" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows provided by financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "terseLabel": "Net cash generated by investing activities", "totalLabel": "Net cash flows provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r66", "r76" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows provided by (used in) investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r66", "r76" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r354", "r525" ] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "iva_CatalysOptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CatalysOptionAgreementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Catalys Option Agreement.", "label": "Catalys Option Agreement [Member]", "terseLabel": "Catalys Option Agreement" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r166", "r270" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r166", "r270" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r166", "r270" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r166", "r270" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r35", "r236" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r35", "r236" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r454" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r451" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r449" ] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits" } } }, "auth_ref": [] }, "iva_CirReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CirReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "CIR receivable", "label": "CIR receivable", "terseLabel": "CIR receivable" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right, Exercised During Period", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ClassOfWarrantOrRightMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of the warrants issued by the entity.", "label": "Class Of Warrant Or Right, Maturity Term", "terseLabel": "Maturity term of warrants" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ClassOfWarrantOrRightSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Subscription Price", "terseLabel": "Subscription price per warrant" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r129", "r160", "r161", "r185", "r186", "r292" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r129", "r160", "r161", "r185", "r186", "r292" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r274", "r277" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r274", "r277" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r160", "r161", "r185", "r186" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r160", "r161", "r185", "r186" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r58", "r249" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r58", "r249" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Inventories" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfOtherProvisionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOtherProvisionsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [domain]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r54", "r245" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r14", "r226" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r14", "r226" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r54", "r245" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r202", "r286", "r323" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r202", "r286", "r323" ] }, "iva_ClinicalDevelopmentProgramOfLanifibranorInJapanPhase1TrialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ClinicalDevelopmentProgramOfLanifibranorInJapanPhase1TrialMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the clinical development program of lanifibranor in Japan, Phase 1 trial.", "label": "Clinical development program of lanifibranor in Japan, Phase 1 trial [Member]", "terseLabel": "Clinical development program of lanifibranor in Japan, Phase I trial" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at the end of period", "verboseLabel": "Exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r535" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r455" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r455" ] }, "iva_CollaborativeArrangementMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CollaborativeArrangementMilestonePaymentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the cash inflows from milestone payments in collaborative arrangements.", "label": "Collaborative Arrangement, Milestone Payments Received", "terseLabel": "Milestone payments received" } } }, "auth_ref": [] }, "iva_CommercialExploitationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CommercialExploitationMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for when a product implementing one or more of his inventions enters the commercial exploitation phase (generates revenues) in one of the stipulated territories.", "label": "Commercial Exploitation [Member]", "terseLabel": "Commercial exploitation" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "verboseLabel": "Amount committed to pay" } } }, "auth_ref": [] }, "iva_CommitmentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CommitmentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commitments received.", "label": "Commitments Received", "terseLabel": "Total commitments received" } } }, "auth_ref": [] }, "ifrs-full_CommunicationAndNetworkEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CommunicationAndNetworkEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Communication and network equipment [member]", "terseLabel": "Technical facilities, equipment and tooling" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r460" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r459" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r461" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r458" ] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information." } } }, "auth_ref": [] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r300" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r300" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r81", "r83", "r93", "r238", "r257", "r294", "r327", "r356" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [member]", "terseLabel": "IT equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Computer software [member]", "terseLabel": "Software licenses" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in progress [member]", "terseLabel": "Property, plant and equipment in progress" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V.", "verboseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given", "verboseLabel": "Commitment amount" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r535" ] }, "iva_ContractualCommitmentsBonusOrMalusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ContractualCommitmentsBonusOrMalusAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of bonus or malus amount included in contractual commitments.", "label": "Contractual Commitments, Bonus Or Malus Amount", "terseLabel": "Bonus or malus capped amount" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r168" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "iva_CreditAgricoleBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CreditAgricoleBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Credit Agricole Bank.", "label": "Crdit Agricole bank", "terseLabel": "Crdit Agricole bank" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Exposure to foreign exchange risk" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r123", "r124", "r125", "r126", "r169" ] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r539", "r542" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r89", "r315", "r356" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "iva_CurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CurrentAssetsExcludingDeferredAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Current assets excluding deferred assets", "label": "Current assets excluding deferred assets", "totalLabel": "Total current assets" } } }, "auth_ref": [] }, "iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "label": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "terseLabel": "Short-term debt" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r108" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current derivative financial liabilities", "terseLabel": "Short-term debt - derivatives", "verboseLabel": "Derivative liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r539" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r91", "r316", "r356" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r535" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } } }, "auth_ref": [ "r510" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Tax receivables", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r308" ] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "verboseLabel": "CIR" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income)", "negatedLabel": "Current taxes" } } }, "auth_ref": [ "r337", "r380" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current taxes" } } }, "auth_ref": [ "r506" ] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "VAT payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r542" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r540" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r410", "r499" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r401", "r490" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r402", "r491" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r402", "r491" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r400", "r489" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r400", "r489" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r400", "r489" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r403", "r492" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r405", "r494" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r405", "r494" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r409", "r498" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r407", "r496" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r404", "r493" ] }, "iva_DailyDoseOfEmpagliflozinInTrial": { "xbrltype": "massItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DailyDoseOfEmpagliflozinInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of daily dosage of empagliflozin in the trial.", "label": "Daily Dose Of Empagliflozin In Trial", "terseLabel": "Daily dose of empagliflozin in trial" } } }, "auth_ref": [] }, "iva_DailyDoseOfLanifibranorInTrial": { "xbrltype": "massItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DailyDoseOfLanifibranorInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Daily dose of lanifibranor in trial", "label": "Daily dose of lanifibranor in trial", "terseLabel": "Daily dose of lanifibranor in trial" } } }, "auth_ref": [] }, "iva_DavidNikodemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DavidNikodemMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem", "terseLabel": "David Nikodem" } } }, "auth_ref": [] }, "iva_DebtFinancial": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DebtFinancial", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt, financial", "label": "Debt, financial", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Debt" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.", "label": "Decrease in borrowings through repayment of lease liabilities", "negatedLabel": "Repayment of lease liabilities" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments of bank borrowings", "label": "Decrease in borrowings through repayments of bank borrowings", "negatedLabel": "Repayment of bank borrowings" } } }, "auth_ref": [] }, "iva_DecreaseInFinancialDebtThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreaseInFinancialDebtThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in financial debt through repayments.", "label": "Decrease in financial debt through repayments", "negatedLabel": "Repayments" } } }, "auth_ref": [] }, "iva_DecreaseInLeaseLiabilitiesThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreaseInLeaseLiabilitiesThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in lease liabilities through repayments.", "label": "Decrease in lease liabilities through repayments" } } }, "auth_ref": [] }, "iva_DecreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases to intangible assets other than goodwill.", "label": "Decreases in intangible assets other than goodwill", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_DecreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DecreasesInPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases in property, plant and equipment", "label": "Decreases in property, plant and equipment", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_DeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DeferredAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred assets", "label": "Deferred assets" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax asset", "verboseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r219", "r309", "r312" ] }, "iva_DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount due to unrecognized deferred tax assets related to tax losses and temporary differences for reconciliation between accounting profit and tax expense income.", "label": "Deferred Tax Assets Related To Tax Losses And Temporary Differences Unrecognized", "negatedLabel": "Non recognition of deferred tax assets related to tax losses and temporary differences" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "negatedLabel": "Deferred taxes" } } }, "auth_ref": [ "r7", "r220" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "terseLabel": "Benefit obligation at December 31", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r515" ] }, "iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of increase of Hemoglobin in patients with MASH and T2D.", "label": "Demonstrated Increase of Hemoglobin in Patients With MASH And T2D", "terseLabel": "Percentage of increase observed in the placebo arm" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of reduction in Hemoglobin among patients with MASH and T2D.", "label": "Demonstrated Reduction of Hemoglobin in Patients With MASH And T2D", "terseLabel": "Percentage reduction in results on treatments" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy", "label": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy", "verboseLabel": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.", "label": "Demonstrated Reduction Of Hepatic Steatosis Measured By MRI-PDFF", "terseLabel": "Reduction in hepatic steatosis (in percent)" } } }, "auth_ref": [] }, "iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DemonstratedSignificantRelativeReductionInVatSatRatioInPatients", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of significant relative reduction in VAT / SAT ratio in patients.", "label": "Demonstrated Significant Relative Reduction in VAT/SAT Ratio in Patients", "terseLabel": "Significant relative reduction in VAT/SAT ratio (in percent)" } } }, "auth_ref": [] }, "iva_DepartureOfEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DepartureOfEmployeesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the departure of employees.", "label": "Departure of employees [Member]", "terseLabel": "Departure of employees" } } }, "auth_ref": [] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, right-of-use assets", "terseLabel": "Depreciation expense" } } }, "auth_ref": [ "r116", "r192" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial liabilities", "terseLabel": "Derivatives", "verboseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r539" ] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments", "terseLabel": "Derivative instruments" } } }, "auth_ref": [] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Derivatives [member]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r357", "r360", "r367", "r377" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for borrowings [text block]", "terseLabel": "Loans and borrowings" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for derivative financial instruments [text block]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for derivative financial instruments. [Refer: Classes of financial instruments [domain]; Derivatives [member]]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Current and deferred tax" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Lease contracts" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r536" ] }, "iva_DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other income.", "label": "Description Of Accounting Policy For Other Income [Policy Text Block]", "terseLabel": "Other income" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "verboseLabel": "Property, plant, and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Other provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments plans" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r536" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r75", "r209" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Average life (years)" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r138" ] }, "iva_DetteBsaBei2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DetteBsaBei2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to DETTE BSA BEI 2022.", "label": "DETTE BSA BEI 2022 [Member]", "terseLabel": "DETTE BSA BEI 2022" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r43", "r44" ] }, "iva_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors", "terseLabel": "Directors" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about actuarial gains (losses) recognized in comprehensive income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Actuarial Gains And Losses Recognized In Comprehensive Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of actuarial gains and losses recognized in comprehensive income" } } }, "auth_ref": [] }, "iva_DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about assumptions used to measure Retirement Benefit Obligations.", "label": "Disclosure Of Assumptions Used To Measure Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of assumptions used to measure retirement benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [text block]", "terseLabel": "Schedule of attribution of expenses by nature to their function" } } }, "auth_ref": [ "r532", "r535" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r532", "r535" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Debt, Derivatives and Royalty certificates liabilities" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents balance from the statement of cash flows" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents balance from the statement of cash flows" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "terseLabel": "Schedule of changes in borrowings" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r202", "r286", "r323" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r202", "r286", "r323" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivities" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments related to operational activities" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of commitments related to operational activities.", "label": "Disclosure of Commitments Related Operational Activities [Table Text Block]", "terseLabel": "Schedule of Commitments given and received" } } }, "auth_ref": [] }, "iva_DisclosureOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfDeferredTaxAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of deferred tax assets.", "label": "Deferred tax asset." } } }, "auth_ref": [] }, "iva_DisclosureOfDeferredTaxAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfDeferredTaxAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of deferred tax assets.", "label": "Disclosure Of Deferred Tax Assets [Table Text Block]", "terseLabel": "Schedule of deferred tax assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAsset" ], "lang": { "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "terseLabel": "Deferred tax asset" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Provisions for retirement benefit obligations." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDepositaryReceiptsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDepositaryReceiptsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Schedule disclosing information about depositary receipts.", "terseLabel": "Company information" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDepositaryReceiptsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDepositaryReceiptsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of depositary receipts [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information about depositary receipts." } } }, "auth_ref": [ "r535" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Debt, Derivatives and Royalty certificates liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r530" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Debt, Derivatives and Royalty certificates liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r530" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r147", "r153", "r162", "r266" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r58", "r249" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare" ], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Basic and diluted loss per share" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r46" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r22" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events after the reporting date" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of breakdown of expense recognized for the period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "verboseLabel": "Financial income and expenses" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [line items]", "terseLabel": "Cash and cash equivalents balance from the statement of cash flows" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r162", "r266" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial assets and liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r170" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r147", "r153", "r162", "r266" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [line items]", "terseLabel": "Accounting principles" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r162", "r266" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Summary of entity's geographical split" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [line items]", "terseLabel": "Geographical split" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTax" ], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income tax" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of measurements for share options granted" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r139" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r58", "r249" ] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r87" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventories" ], "lang": { "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethod" ], "lang": { "en-us": { "role": { "label": "Disclosure of investments accounted for using equity method [text block]", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]", "terseLabel": "Accounting principles" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r210", "r288", "r301" ] }, "iva_DisclosureOfMaturityAnalysisForDerivativeAndNonDerivativeFinancialLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfMaturityAnalysisForDerivativeAndNonDerivativeFinancialLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of a maturity analysis for derivative and non-derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows.", "label": "Disclosure Of Maturity Analysis For Derivative And Non Derivative Financial Liabilities [Table Text Block]", "terseLabel": "Schedule of maturity analysis of financial liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial risk management" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r148", "r149" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Events after the reporting date" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and AGA" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of stock option plans" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r134", "r262" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of other liabilities [text block]", "terseLabel": "Other current and non-current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of other non-current assets [text block]", "terseLabel": "Other non-current assets" } }, "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income (expense) [text block]", "terseLabel": "Other operating income and expenses" } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsAbstract", "lang": { "en-us": { "role": { "label": "Provisions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [text block]", "terseLabel": "Schedule of provisions" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r54", "r245" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r54", "r245" ] }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of profit (loss) from operating activities [text block]", "terseLabel": "Operating expenses" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r16" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Accounting principles", "verboseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r14", "r226" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisions" ], "lang": { "en-us": { "role": { "label": "Disclosure of provisions [text block]", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in property, plant and equipment, including right-of-use assets [text block]", "terseLabel": "Reconciliation of changes in property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in property, plant and equipment, including right-of-use assets." } } }, "auth_ref": [ "r509" ] }, "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]", "terseLabel": "Schedule of investment in Hepalys is accounted for using the equity method of accounting" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Total for all associates [member]]" } } }, "auth_ref": [ "r99" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related-party transactions" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue [text block]", "terseLabel": "Revenues and other income" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } } }, "auth_ref": [ "r21" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r203", "r287", "r324" ] }, "iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of share of net profit (loss) - Equity method" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantActuarialAssumptionsUsedToDeterminePresentValueOfDefinedBenefitObligationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "terseLabel": "Schedule of sensitivity analysis" } }, "en": { "role": { "documentation": "The disclosure of significant actuarial assumptions used to determine the present value of the defined benefit obligation." } } }, "auth_ref": [ "r20", "r229" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [line items]", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r39", "r41", "r102", "r280" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r39", "r41", "r101", "r279" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Deferred tax asset" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r8", "r221" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]", "terseLabel": "Schedule of main characteristics of share-based payment plan" } }, "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r137", "r263" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the interim condensed consolidated statement of financial position" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r137", "r263" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r531" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Trade receivables, tax receivables and other current assets" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r531" ] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Text Block]", "terseLabel": "Trade payables and short-term contract liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables and others break down" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Related-party transactions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of compensation awarded to members of executive team" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r33", "r234" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Related-party transactions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r35", "r236" ] }, "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement", "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]", "terseLabel": "Schedule of valuation approach for BSA arrangement" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate, measurement input [member]", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r527" ] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposals, property, plant and equipment", "verboseLabel": "Accumulated depreciation on the disposed technical facilities" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r12", "r224" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r509" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r398" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r397", "r398", "r421" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r397", "r398", "r421", "r464" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r392" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r398" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r442" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_DonationsAndSubsidiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DonationsAndSubsidiesExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Donations and subsidies expense", "negatedLabel": "Tax-exempt donations" } } }, "auth_ref": [ "r535" ] }, "iva_DrawdownOfBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DrawdownOfBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for drawdown of borrowings", "label": "Drawdown of borrowings [Member]", "terseLabel": "Drawdown of borrowings" } } }, "auth_ref": [] }, "iva_DurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "DurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Duration of clinical trial", "label": "Duration of Clinical Trial", "terseLabel": "Duration of clinical trial" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r453" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / (losses)" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r69", "r70" ] }, "iva_EliminationOfDownstreamSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EliminationOfDownstreamSales", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of elimination of downstream sales.", "label": "Elimination Of Downstream Sales", "negatedLabel": "Elimination of downstream sales" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } } }, "auth_ref": [ "r199", "r293", "r336", "r383" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employee-related payables" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r394" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r394" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r394" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r504" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r394" ] }, "iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity's share of net assets in investments accounted for using the equity method", "label": "Entity's share of net assets in investments accounted for using the equity method", "terseLabel": "Group's share" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r394" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r505" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r447" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r500" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r500" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r500" ] }, "iva_EquipmentAndToolingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EquipmentAndToolingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equipment and tooling.", "label": "Equipment and tooling" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r80", "r82", "r103", "r104", "r106", "r237", "r256", "r282", "r283", "r291", "r311", "r320" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "terseLabel": "Total equity and liabilities", "totalLabel": "Total liabilities and shareholders' equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r311" ] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r457" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r414", "r425", "r435", "r468" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r411", "r422", "r432", "r465" ] }, "iva_EstimatedAmountPayableUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EstimatedAmountPayableUnderAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount payable under the agreement.", "label": "Estimated Amount Payable Under Agreement", "terseLabel": "Estimated amount payable" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EuropeanInvestmentBankWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to European Investment Bank warrants.", "label": "European Investment Bank Warrants [Member]", "terseLabel": "EIB warrants" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EuropeanInvestmentBankWarrantsTrancheBMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for European Investment bank warrants Tranche B.", "label": "European Investment Bank Warrants Tranche B [Member]", "terseLabel": "EIB Warrants Tranche B" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsTrancheaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "EuropeanInvestmentBankWarrantsTrancheaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for European Investment bank warrants Tranche A.", "label": "European Investment Bank Warrants Tranche A [Member]", "terseLabel": "EIB Warrants Tranche A" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r463" ] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of stock and warrants.", "label": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "iva_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The expected volatility of other equity instruments granted.", "label": "Expected Volatility, Other Equity Instruments Granted", "terseLabel": "Expected volatility" } } }, "auth_ref": [] }, "iva_ExpenseFromAcceleratedVestingOfShareBasedPaymentAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpenseFromAcceleratedVestingOfShareBasedPaymentAwards", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from accelerated vesting of share-based payment awards", "label": "Expense from accelerated vesting of share-based payment awards", "negatedLabel": "Share-based compensation expense", "terseLabel": "Share-based compensation expense" } } }, "auth_ref": [] }, "iva_ExpenseFromAmendmentOfShareBasedPaymentPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpenseFromAmendmentOfShareBasedPaymentPlan", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from amendment of share-based payment plan.", "label": "Expense from amendment of share-based payment plan" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions", "terseLabel": "Expense from share-based payment transactions", "verboseLabel": "Share-based compensation expense" } } }, "auth_ref": [ "r141", "r264" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Sharebased compensation expense" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_ExpenseOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseOfRestructuringActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Expense of restructuring activities", "negatedLabel": "Restructuring expenses", "terseLabel": "Restructuring expenses" } } }, "auth_ref": [ "r334" ] }, "iva_ExpensesUnderSocialSecurityAgreementInConnectionWithEmployeeSDeparture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpensesUnderSocialSecurityAgreementInConnectionWithEmployeeSDeparture", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expenses under social security agreement in connection with employee's departure.", "label": "Expenses under social security agreement in connection with employee's departure" } } }, "auth_ref": [] }, "iva_ExpensesUnderTransactionalMemorandumOfUnderstandingInConnectionWithEmployeeSDeparture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExpensesUnderTransactionalMemorandumOfUnderstandingInConnectionWithEmployeeSDeparture", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expenses under transactional memorandum of understanding in connection with employee's departure.", "label": "Expenses under transactional memorandum of understanding in connection with employee's departure" } } }, "auth_ref": [] }, "iva_ExperiencedInflationDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ExperiencedInflationDuringPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "Experienced inflation during the period.", "label": "Experienced inflation during the period" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "France" } } }, "auth_ref": [] }, "iva_FairValueOfEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfEquityInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of equity instruments.", "label": "Fair Value Of Equity Instruments", "terseLabel": "Fair Value (in millions of euros)" } } }, "auth_ref": [] }, "iva_FairValueOfOptionToAcquireSharesInAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfOptionToAcquireSharesInAssociate", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of option to acquire shares in associate", "label": "Fair value of option to acquire shares in associate", "terseLabel": "Fair value of option to acquire shares in associate" } } }, "auth_ref": [] }, "iva_FairValueOfPotentialShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfPotentialShares", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of potential shares", "label": "Fair value of potential shares" } } }, "auth_ref": [] }, "iva_FairValueOfPotentialWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfPotentialWarrants", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of potential warrants.", "label": "Fair value of potential warrants" } } }, "auth_ref": [] }, "iva_FairValueOfSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfSharesIssued", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of shares issued.", "label": "Fair value of shares issued" } } }, "auth_ref": [] }, "iva_FairValueOfWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FairValueOfWarrantsOutstanding", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants outstanding", "label": "Fair value of warrants outstanding", "terseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines", "terseLabel": "Fibroscan machines" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche (Tranche A)", "verboseLabel": "EIB Tranche A 2022" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB", "verboseLabel": "Finance contract with European Investment Bank" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche (Tranche B)", "verboseLabel": "EIB Tranche B 2024" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Net financial income", "totalLabel": "Financial income (loss)" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r146", "r151", "r152", "r155", "r274", "r275", "r277", "r366" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at amortised cost, category [member]", "terseLabel": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r164", "r268" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value", "verboseLabel": "Assets, fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r146" ] }, "iva_FinancialIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "The entire disclosure of financial income and expenses.", "label": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialIncomeAndExpensesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Financial Income And Expenses [Line Items]", "verboseLabel": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialIncomeAndExpensesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of financial income and expenses.", "label": "Financial Income And Expenses [Table]" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialInstrumentDerivativesCallOptionStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialInstrumentDerivativesCallOptionStrikePrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Strike price or exercise price of a derivative financial instrument that gives the holder the right, but not the obligation, to purchase or sell an underlying asset.", "label": "Financial Instrument, Derivatives, Call Option, Strike Price", "terseLabel": "Call option strike price" } } }, "auth_ref": [] }, "iva_FinancialInstrumentsDerivativesCallOptionConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancialInstrumentsDerivativesCallOptionConversionRatio", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of derivative instrument that gives the holder the right, but not the obligation, to purchase or sell an underlying asset.", "label": "Financial Instruments, Derivatives, Call Option, Conversion Ratio", "terseLabel": "Call option, conversion ratio" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, category [member]", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r165", "r269" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r167", "r187", "r271" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r163", "r267" ] }, "iva_FinancingArrangementInThreeTranches2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches.", "label": "Financing arrangement in three tranches 2024 [Member]", "terseLabel": "2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche I.", "label": "Financing arrangement in three tranches 2024, Tranche I [Member]", "terseLabel": "Tranche I, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIPhaseIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIPhaseIMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche I, phase I.", "label": "Financing arrangement in three tranches 2024, Tranche I, phase I [Member]", "verboseLabel": "Tranche I, phase I, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIPhaseIiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIPhaseIiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche I, phase II.", "label": "Financing arrangement in three tranches 2024, Tranche I, phase II [Member]", "verboseLabel": "Tranche I, phase II, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIiAndTrancheIiiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIiAndTrancheIiiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche II and Tranche III.", "label": "Financing arrangement in three tranches 2024, Tranche II and Tranche III [Member]", "terseLabel": "Tranche II and Tranche III, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche II.", "label": "Financing arrangement in three tranches 2024, Tranche II [Member]", "terseLabel": "Tranche II, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIiiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingArrangementInThreeTranches2024TrancheIiiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche III.", "label": "Financing arrangement in three tranches 2024, Tranche III [Member]", "terseLabel": "Tranche III, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks", "terseLabel": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Fixtures and fittings [member]", "terseLabel": "Fixtures and fittings" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } } }, "auth_ref": [ "r26", "r230", "r302" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } } }, "auth_ref": [ "r26", "r230", "r302" ] }, "iva_ForeignExchangeRateWithReasonablyPossibleIncreaseInRiskAssumption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ForeignExchangeRateWithReasonablyPossibleIncreaseInRiskAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate with reasonably possible increase in risk assumption", "label": "Foreign exchange rate with reasonably possible increase in risk assumption", "terseLabel": "Impact of a 5% change in exchange rate at the end of period" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange rates [abstract]", "terseLabel": "Foreign currency translation" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r452" ] }, "iva_FredericCrenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FredericCrenMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren", "label": "Frederic Cren [Member]", "terseLabel": "Frederic Cren" } } }, "auth_ref": [] }, "iva_FurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "FurnitureMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for furniture.", "label": "Furniture" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r18", "r228" ] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Gains (losses) on change in fair value of derivatives", "terseLabel": "Losses on fair value variation" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Gains on change in fair value of derivatives", "terseLabel": "Gain on fair value variation" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_GainsOnDisposalsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnDisposalsOfInvestments", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Gains on disposals of investments", "terseLabel": "Gain on disposals of assets" } }, "en": { "role": { "documentation": "The gain on the disposal of investments." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "auth_ref": [ "r535" ] }, "iva_GeneralFacilitiesMiscellaneousFixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "GeneralFacilitiesMiscellaneousFixturesAndFittingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general facilities, miscellaneous fixtures and fittings.", "label": "General facilities, miscellaneous fixtures and fittings" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r183", "r341", "r363", "r365", "r379" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r183", "r341", "r363", "r365", "r379" ] }, "iva_GoingConcernLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "GoingConcernLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Going Concern [Line Items]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "iva_GoingConcernTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "GoingConcernTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to going concern.", "label": "Going Concern [Table]" } } }, "auth_ref": [] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r48", "r50", "r142", "r239", "r241", "r265", "r303" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross carrying amount [member]", "terseLabel": "Laboratory inventories", "verboseLabel": "Gross" } } }, "auth_ref": [ "r11", "r55", "r62", "r65", "r142", "r152", "r155", "r223", "r246", "r252", "r255", "r275", "r277", "r366" ] }, "iva_GrossProceedsFromIssuanceOfEquityAndRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "GrossProceedsFromIssuanceOfEquityAndRoyaltyCertificates", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gross proceeds from the issuance of share capital and royalty certificates.", "label": "Gross Proceeds from Issuance of Equity and Royalty Certificates", "terseLabel": "Gross proceeds from issuance of equity and royalty certificates" } } }, "auth_ref": [] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Historical volatility for shares, measurement input [member]", "terseLabel": "Volatility" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r358" ] }, "iva_HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the holding period of awards granted in share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Holding Period Of Awards Granted In Share-Based Payment Arrangement", "terseLabel": "Holding period (year)" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r397", "r398", "r421" ] }, "iva_IfFiveDayVolumeWeightedAveragePriceMoreThan1.35Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfFiveDayVolumeWeightedAveragePriceMoreThan1.35Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario when 5D-VWAP is more than \u20ac1.35.", "label": "If Five day Volume Weighted Average Price More Than \u20ac1.35 [Member]", "terseLabel": "If five day volume weighted average price more than \u20ac1.35" } } }, "auth_ref": [] }, "iva_IfrsBankOverdraftsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsBankOverdraftsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Bank Overdrafts [Member]", "label": "IFRS Bank Overdrafts [Member]", "terseLabel": "Bank overdraft" } } }, "auth_ref": [] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and Cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Ifrs Class of Warrant or Right [Axis]" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Ifrs Class of Warrant or Right [Domain]" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant", "verboseLabel": "Exercise price per warrant" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares per warrant", "verboseLabel": "Number of shares per instrument" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "IFRS Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of shares underlying in EIB", "verboseLabel": "Number of shares callable by warrants" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "verboseLabel": "Number of BSA outstanding" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Company information", "terseLabel": "Revenues and other income", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "iva_IfrsDisclosureOfOperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsDisclosureOfOperatingExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating expenses" } } }, "auth_ref": [] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInEmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsIncreaseDecreaseInEmployeeRelatedPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in employee related payables.", "label": "IFRS Increase (Decrease) In Employee Related Payables", "terseLabel": "Increase in employee-related payables" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsIncreaseDecreaseInOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other current liabilities of the entity.", "label": "IFRS Increase (Decrease) In Other Current Liabilities", "terseLabel": "Decrease in other current liabilities" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsIncreaseDecreaseInPrepaidExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "IFRS Increase (Decrease) in Prepaid Expense", "negatedLabel": "Increase (decrease) in prepaid expenses" } } }, "auth_ref": [] }, "iva_IfrsLeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsLeaseAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for lease agreements.", "label": "ifrs Lease Agreements [Member]", "terseLabel": "Lease" } } }, "auth_ref": [] }, "iva_IfrsNumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsNumberOfOperatingSegments", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments", "terseLabel": "Number of operating segments" } } }, "auth_ref": [] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_IfrsProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "IFRS Proceeds from Issuance of Warrants", "terseLabel": "Issue of prefunded warrants" } } }, "auth_ref": [] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "verboseLabel": "Research and development expenses" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses", "verboseLabel": "Marketing - business development expenses" } } }, "auth_ref": [] }, "iva_IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carry forwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Ifrs Schedule of Components of Income Tax Expense Benefit [Table text block]", "terseLabel": "Schedule of income tax expense" } } }, "auth_ref": [] }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "auth_ref": [] }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "verboseLabel": "Vesting period (year)" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche one" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche three" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche two" } } }, "auth_ref": [] }, "iva_IfrsSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsSharePrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "IFRS Share price", "terseLabel": "Stock price" } } }, "auth_ref": [] }, "iva_IfrsSharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsSharesIssuedPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Ifrs Shares Issued, Price Per Share", "terseLabel": "Price per share" } } }, "auth_ref": [] }, "iva_IfrsVestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsVestingAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "auth_ref": [] }, "iva_IfrsVestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IfrsVestingDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossRightofuseAssets", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, right-of-use assets", "terseLabel": "Impairment loss on right of use assets" } } }, "auth_ref": [ "r509" ] }, "iva_ImpairmentOfFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ImpairmentOfFixedAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Impairment of fixed assets.", "label": "Impairment of fixed assets" } } }, "auth_ref": [] }, "iva_ImpliedStockOptionsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ImpliedStockOptionsFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Implied stock options fair value", "label": "Implied stock options fair values" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax", "negatedTerseLabel": "Income (expense) tax", "negatedTotalLabel": "Actual income tax benefit" } } }, "auth_ref": [ "r2", "r3", "r4", "r37", "r98", "r173", "r215", "r216", "r217", "r330" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r72", "r347" ] }, "iva_IncreaseDecreaseInBorrowingsDueToSettlementOfDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInBorrowingsDueToSettlementOfDerivativeInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in borrowings upon settlement of derivative instruments.", "label": "Increase (Decrease) In Borrowings Due To Settlement Of Derivative Instruments", "terseLabel": "Settlement of derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInBorrowingsThroughIssueOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInBorrowingsThroughIssueOfRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in borrowings due to issue of royalty certificates.", "label": "Increase (Decrease) In Borrowings Through Issue Of Royalty Certificates", "terseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "terseLabel": "Decrease in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r74", "r208" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r74", "r208" ] }, "iva_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period.", "label": "Increase (Decrease) In Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption, Percent", "terseLabel": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption (as a percent)" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFairValueOfDerivativeFinancialLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFairValueOfDerivativeFinancialLiability", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in the fair value of a derivative financial liability.", "label": "Increase (Decrease) in Fair Value of Derivative Financial Liability", "terseLabel": "Decrease in fair Value of derivative" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFairValueOfFinancialLiabilityDueToReasonablyPossibleDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFairValueOfFinancialLiabilityDueToReasonablyPossibleDecreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in fair value of financial liability due to reasonably possible decrease in designated risk component.", "label": "Increase (decrease) in fair value of financial liability due to reasonably possible decrease in designated risk component" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFairValueOfFinancialLiabilityDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFairValueOfFinancialLiabilityDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in fair value of financial liability due to reasonably possible increase in designated risk component.", "label": "Increase (decrease) in fair value of financial liability due to reasonably possible increase in designated risk component" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialDebtThroughFairValueMovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialDebtThroughFairValueMovements", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in financial debt through fair value movements.", "label": "Increase (decrease) in financial debt through fair value movements", "terseLabel": "Fair value Variation" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialDebtThroughForeignExchangeDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialDebtThroughForeignExchangeDifferences", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in financial debt through foreign exchange differences.", "label": "Increase (decrease) in financial debt through foreign exchange differences", "terseLabel": "Effect of movements in exchange rates" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleDecreaseInDesignatedRiskComponent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of a decrease in a designated risk component that was reasonably possible at the end of the reporting period.", "label": "Increase (Decrease) In Financial Instrument Due To Reasonably Possible Decrease In Designated Risk Component", "terseLabel": "Impact of reasonably possible decrease in assumption" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase (decrease) in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "label": "Increase (Decrease) In Financial Instrument Due To Reasonably Possible Increase (Decrease) In Designated Risk Component", "terseLabel": "Impact of reasonably possible increase (decrease) in assumption" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInProbabilityOfSuccessOfRegulatoryApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInProbabilityOfSuccessOfRegulatoryApproval", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase (decrease) in a probability of success of regulatory approval that was reasonably possible at the end of the reporting period.", "label": "Increase (decrease) In Financial Instrument Due To Reasonably Possible Increase (Decrease) In Probability Of Success Of Regulatory Approval", "terseLabel": "Amortized cost" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase in a designated risk component that was reasonably possible at the end of the reporting period.", "label": "Increase (Decrease) In Financial Instrument Due To Reasonably Possible Increase In Designated Risk Component", "terseLabel": "Impact of reasonably possible increase in assumption" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in lease liabilities during the period.", "label": "Increase (Decrease) in Lease Liabilities", "terseLabel": "Increase (decrease) in lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Gain / (Expense) for the period" } } }, "auth_ref": [ "r511" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "verboseLabel": "Number of shares" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r201", "r285", "r322" ] }, "iva_IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other miscellaneous current liabilities of the entity.", "label": "Increase (Decrease) In Other Miscellaneous Current Liabilities", "terseLabel": "Decrease in other miscellaneous liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInOtherMiscellaneousIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInOtherMiscellaneousIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other miscellaneous income.", "label": "Increase (decrease) in other miscellaneous income" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInOtherOperatingExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other operating expense", "label": "Increase (decrease) in other operating expense", "terseLabel": "Increase in other operating expense" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r509" ] }, "iva_IncreaseDecreaseInSalesTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInSalesTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in sales tax liabilities of the entity.", "label": "Increase (Decrease) In Sales Tax Liabilities", "terseLabel": "Increase in VAT payable" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares resulting from the exercise and vesting of equity instruments.", "label": "Increase Decrease In Shares Through Exercise And Vesting Of Equity Instruments", "terseLabel": "Vesting of bonus shares (in shares)" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Decrease in trade accounts payable" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseInTradeAndOtherCurrentReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in trade and other current receivables.", "label": "Increase (Decrease) in Trade and other current receivables", "terseLabel": "Increase (decrease) in trade and other current receivables." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r525" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r533" ] }, "iva_IncreaseDecreaseThroughCapitalVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseThroughCapitalVariations", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through capital variations, equity", "label": "Increase (decrease) through capital variations", "terseLabel": "Capital variations" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Vesting of bonus shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r533" ] }, "iva_IncreaseDecreaseThroughIssuanceOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the issuance of warrants.", "label": "Increase Decrease Through Issuance Of Warrants, Equity", "terseLabel": "Issue of prefunded warrants" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "negatedLabel": "Other changes (IFRIC - IAS 19)" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r511" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, property, plant and equipment including right-of-use assets", "terseLabel": "Others" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r509" ] }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r298" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r299" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r299" ] }, "iva_IncreaseInBorrowingsDueToSubscriptionOfShortTermBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInBorrowingsDueToSubscriptionOfShortTermBankBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase in borrowings due to subscription of short-term bank borrowings.", "label": "Increase In Borrowings Due To Subscription of Short-term Bank Borrowings", "terseLabel": "Subscription of short-term bank borrowings" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInBorrowingsThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through capitalized interest.", "label": "Increase in borrowings through capitalized interest", "terseLabel": "Capitalized interests" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughNewLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInBorrowingsThroughNewLeases", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in borrowings through new leases.", "label": "Increase In Borrowings Through New Leases", "verboseLabel": "Subscription of lease liabilities" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfLongTermDerivativeInstrumentsAndBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInBorrowingsThroughSubscriptionOfLongTermDerivativeInstrumentsAndBankBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings due to subscription of long-term derivative instruments and bank borrowings.", "label": "Increase In Borrowings Through Subscription Of Long-term Derivative Instruments and Bank Borrowings", "terseLabel": "Subscription of long-term derivatives instruments and bank borrowings" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfShortTermDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInBorrowingsThroughSubscriptionOfShortTermDerivativeInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings due to subscription of short-term derivative instruments.", "label": "Increase In Borrowings Through Subscription Of Short-term Derivative Instruments", "terseLabel": "Subscription of short-term derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseInFinancialDebtThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInFinancialDebtThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in financial debt through capitalized interest", "label": "Increase in financial debt through capitalized interest", "terseLabel": "Capitalized interest" } } }, "auth_ref": [] }, "iva_IncreaseInLeaseLiabilitiesThroughNewLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInLeaseLiabilitiesThroughNewLeases", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in lease liabilities through new leases.", "label": "Increase in lease liabilities through new leases" } } }, "auth_ref": [] }, "iva_IncreaseInSharesThroughIssueOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseInSharesThroughIssueOfOrdinaryShares", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in shares resulting from the issuance of shares.", "label": "Increase In Shares Through Issue of Ordinary Shares", "terseLabel": "Issue of ordinary shares (in shares)" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.", "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments", "terseLabel": "Change in fair value of derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.", "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates", "terseLabel": "Exchange rate change" } } }, "auth_ref": [] }, "iva_IncreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases to intangible assets other than goodwill.", "label": "Increases in intangible assets other than goodwill", "terseLabel": "Increases" } } }, "auth_ref": [] }, "iva_IncreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IncreasesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases in property, plant and equipment", "label": "Increases in property, plant and equipment", "terseLabel": "Increases" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r418", "r429", "r439", "r463", "r472", "r476", "r484" ] }, "iva_InflationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InflationRiskMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for inflation risk.", "label": "Inflation Risk [Member]", "terseLabel": "Inflation Risk" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r482" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r399", "r488" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r399", "r488" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r399", "r488" ] }, "ifrs-full_InsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InsuranceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Insurance expense", "negatedLabel": "Insurance" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r57", "r248", "r303" ] }, "ifrs-full_IntangibleAssetsUnderDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsUnderDevelopmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets under development [member]", "terseLabel": "Intangible assets in progress" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r346" ] }, "iva_IntercompanyEliminationsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "IntercompanyEliminationsInAssociates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of intercompany eliminations in associates", "label": "Intercompany Eliminations in Associates", "negatedLabel": "Elimination of unrealized profit on downstream sales" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r535" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r97", "r172", "r180" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } } }, "auth_ref": [ "r510" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_InterestIncomeOnDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnDeposits", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on deposits", "terseLabel": "Interest income on deposits" } } }, "auth_ref": [ "r535" ] }, "iva_InterestOnRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InterestOnRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through interests on royalty certificates.", "label": "Interest On Royalty Certificates", "verboseLabel": "Interests on royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "Interests paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r71" ] }, "ifrs-full_InterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Interest payable", "terseLabel": "Accrued interest payable on loans" } }, "en": { "role": { "documentation": "The amount of interest recognised as a liability." } } }, "auth_ref": [ "r535" ] }, "iva_InventionSPatentabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InventionSPatentabilityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for disclosing an invention to the company that meets the conditions for patentability.", "label": "Invention's Patentability [Member]", "terseLabel": "Invention's patentability" } } }, "auth_ref": [] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]", "terseLabel": "Inventiva S.A" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r23", "r204", "r305", "r386" ] }, "ifrs-full_InventoryWritedown2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InventoryWritedown2011", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Inventory write-down", "terseLabel": "Inventory impairment" } } }, "auth_ref": [ "r24", "r205", "r333" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "netLabel": "Carrying amount", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r100", "r175", "r281", "r304" ] }, "iva_InvestmentThresholdMinimumMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "InvestmentThresholdMinimumMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold minimum maturity term of the investments, considered for determination of discount rate for actuarial assumptions used to determine the present value of a defined benefit obligation.", "label": "Investment, Threshold Minimum Maturity Term", "terseLabel": "Threshold minimum maturity term for Eurozone AA rated corporate bonds" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsAccountedForUsingEquityMethodAbstract", "lang": { "en-us": { "role": { "label": "Investments accounted for using the equity method" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r298" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital", "verboseLabel": "Capital stock" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r382", "r389" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r300" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "JP", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "auth_ref": [] }, "iva_JeremyGoldbergMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "JeremyGoldbergMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Jeremy Goldberg.", "label": "Jeremy Goldberg", "terseLabel": "Jrmy Goldberg" } } }, "auth_ref": [] }, "country_KR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "KR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Net total" } } }, "auth_ref": [ "r32", "r233" ] }, "iva_KeyManagementPersonnelCompensationAdjustmentOfCompensationPostEmploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "KeyManagementPersonnelCompensationAdjustmentOfCompensationPostEmploymentBenefits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation (adjustment of compensation), post-employment benefits", "label": "Key management personnel compensation (adjustment of compensation), post-employment benefits", "terseLabel": "Post-employment benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based payment" } } }, "auth_ref": [ "r31" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short-term benefits" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel of entity or parent [member]", "terseLabel": "Executive and corporate officers" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r34", "r235" ] }, "ifrs-full_LandMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land [member]", "terseLabel": "Land" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r338" ] }, "iva_LanifibranorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LanifibranorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lanifbranor", "label": "Lanifibranor [Member]", "terseLabel": "Lanifibranor" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Later than five years [member]", "terseLabel": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r117", "r118", "r128", "r194", "r197", "r369", "r373", "r376" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Later than one month and not later than two months [member]", "terseLabel": "Due in 30-60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r366", "r375", "r535" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than three years [member]", "terseLabel": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r369", "r371", "r376" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Later than three years and not later than five years [member]", "terseLabel": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r369", "r372", "r376" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r115" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r352", "r355" ] }, "iva_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LeaseTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term.", "label": "Lease Term", "terseLabel": "Lease term" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D", "label": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]", "terseLabel": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D", "verboseLabel": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D" } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r47", "r49", "r104", "r240", "r283" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r19", "r104", "r283" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r19", "r104", "r283" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r103", "r104", "r106", "r174", "r179", "r282", "r283", "r311" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r206", "r353" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r206", "r353" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "Provision at end of period", "negatedPeriodStartLabel": "Provision at beginning of period", "terseLabel": "Total obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r17", "r227" ] }, "iva_LiabilityForPayrollTaxesRelatingToTaxesOnShareBasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LiabilityForPayrollTaxesRelatingToTaxesOnShareBasedPayment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Liability for payroll taxes relating to taxes on share-based payment.", "label": "Liability for payroll taxes relating to taxes on share-based payment" } } }, "auth_ref": [] }, "iva_LibraryOfCompoundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LibraryOfCompoundsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for library of compounds.", "label": "Library of compounds" } } }, "auth_ref": [] }, "iva_LicenseAgreementIssueOfCreditNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAgreementIssueOfCreditNotes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement, issue of credit notes.", "label": "License agreement, issue of credit notes" } } }, "auth_ref": [] }, "iva_LicenseAgreementPayablesForCreditNotesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAgreementPayablesForCreditNotesIssued", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement, payables for credit notes issued.", "label": "License agreement, payables for credit notes issued", "terseLabel": "License agreement, payables for credit notes issued" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementCreditNoteFourIssuedAsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementCreditNoteFourIssuedAsMilestonePayment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of credit note four issued as a milestone payment in the license and collaboration agreement.", "label": "License And Collaboration Agreement, Credit Note Four Issued As Milestone Payment", "terseLabel": "Credit note D issued payment" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementCreditNoteOneIssuedAsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementCreditNoteOneIssuedAsMilestonePayment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of credit note one issued as a milestone payment in the license and collaboration agreement.", "label": "License And Collaboration Agreement, Credit Note One Issued As Milestone Payment", "terseLabel": "Credit note A issued payment" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementCreditNoteThreeIssuedAsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementCreditNoteThreeIssuedAsMilestonePayment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of credit note three issued as a milestone payment in the license and collaboration agreement.", "label": "License And Collaboration Agreement, Credit Note Three Issued As Milestone Payment", "terseLabel": "Credit note C issued payment" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementCreditNoteTwoIssuedAsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementCreditNoteTwoIssuedAsMilestonePayment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of credit note two issued as a milestone payment in the license and collaboration agreement.", "label": "License And Collaboration Agreement, Credit Note Two Issued As Milestone Payment", "terseLabel": "Credit note B issued payment" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementCreditNotesIssuedAndRecognizedAsReductionInTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementCreditNotesIssuedAndRecognizedAsReductionInTradeReceivables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of credit note issued and recognized as reduction in trade receivables as of the reporting date.", "label": "License And Collaboration Agreement, Credit Notes Issued And Recognized As Reduction In Trade Receivables", "terseLabel": "Reduction to the trade receivables" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMaximumPotentialRegulatoryAndCommercialMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementMaximumPotentialRegulatoryAndCommercialMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of regulatory and commercial milestone payments receivable, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Maximum Potential Regulatory And Commercial Milestone Payments Receivable", "terseLabel": "Maximum potential Regulatory and Commercial Milestone payments receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMilestonePaymentReceivableUponAchievementOfCertainMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementMilestonePaymentReceivableUponAchievementOfCertainMilestone", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment receivable in license and collaboration agreements.", "label": "License and Collaboration Agreement, Milestone Payment Receivable upon Achievement of Certain Milestone", "terseLabel": "Milestone payment receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementNumberOfCreditNotesIssuedInMilestones": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementNumberOfCreditNotesIssuedInMilestones", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of credit notes issued in the license and collaboration agreement.", "label": "License And Collaboration Agreement, Number Of Credit Notes Issued in Milestones", "terseLabel": "Number Of credit notes" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementNumberOfDevelopmentAndRegulatoryMilestones": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementNumberOfDevelopmentAndRegulatoryMilestones", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of development and regulatory milestones to be achieved under the licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Number Of Development And Regulatory Milestones", "terseLabel": "Number of development and regulatory milestones" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementNumberOfSuccessiveTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementNumberOfSuccessiveTargets", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of successive targets to be achieved under the licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Number Of Successive Targets", "terseLabel": "Number of successive targets" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementRevenueFromRecognitionOfFairValueOfSharesAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementRevenueFromRecognitionOfFairValueOfSharesAcquired", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "License and Collaboration Agreement, revenue from recognition of fair value of shares acquired", "label": "License and Collaboration Agreement, revenue from recognition of fair value of shares acquired", "terseLabel": "Revenue from recognition of fair value of shares acquired" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementRevenueFromUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementRevenueFromUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "License and Collaboration Agreement, revenue from upfront payments", "label": "License and Collaboration Agreement, revenue from upfront payments", "terseLabel": "Revenue from upfront payments" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementThreeCreditNotesToBeIssuedUponReceiptOfSecondTrancheOfStructuredFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementThreeCreditNotesToBeIssuedUponReceiptOfSecondTrancheOfStructuredFinancing", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of three credit notes to be issued upon receipt of second tranche of the structured financing under the terms of license and collaboration agreement.", "label": "License And Collaboration Agreement, Three Credit Notes To Be Issued Upon Receipt Of Second Tranche Of Structured Financing", "terseLabel": "Total amount" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee received by the entity, pursuant to licensing and collaborative arrangements.", "label": "License and Collaboration Agreement Upfront Fee Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationArrangementCreditNoteRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicenseAndCollaborationArrangementCreditNoteRecognized", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of credit note recognized during the period under license and collaborative arrangement.", "label": "License And Collaboration Arrangement, Credit Note Recognized", "terseLabel": "License and collaboration arrangement, credit note recognized" } } }, "auth_ref": [] }, "iva_LicensingAgreementWithHepalysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicensingAgreementWithHepalysMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Licensing agreement with Hepalys.", "label": "Licensing Agreement With Hepalys [Member]", "terseLabel": "Licensing agreement with Hepalys" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative arrangements, attributable to withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Received Attributable To Withholding Taxes", "terseLabel": "Amount received attributable to withholding taxes" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainCommercialMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainCommercialMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain commercial milestones, pursuant to licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Maximum Additional Amount Receivable Upon The Achievement Of Certain Commercial Milestones", "verboseLabel": "Maximum additional amount receivable upon the achievement of certain commercial milestones" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain development and regulatory milestones, pursuant to licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Maximum Additional Amount Receivable Upon The Achievement Of Certain Development And Regulatory Milestones", "terseLabel": "Maximum additional amount receivable upon the achievement of certain development and regulatory milestones" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "iva_LiquidityAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LiquidityAgreementTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days used to determine liquidity agreement term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Liquidity Agreement Term", "terseLabel": "Liquidity agreement term" } } }, "auth_ref": [] }, "iva_LiquidityAgreementWithKeplerCheuvreuxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LiquidityAgreementWithKeplerCheuvreuxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Liquidity agreement with Kepler Cheuvreux.", "label": "Liquidity agreement with Kepler Cheuvreux [Member]", "terseLabel": "Liquidity agreement with Kepler Cheuvreux" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings and related derivatives", "verboseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r535" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts", "terseLabel": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_LongTermDepositForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermDepositForwardContractMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term deposit forward contract.", "label": "Long-Term Deposit Forward Contract [Member]", "terseLabel": "Long-term deposit forward contract" } } }, "auth_ref": [] }, "iva_LongTermDepositsClosed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermDepositsClosed", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of long-term deposits closed by the entity.", "label": "Long-term Deposits Closed", "terseLabel": "Closing long term deposit" } } }, "auth_ref": [] }, "iva_LongTermDepositsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermDepositsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the long-term deposits of the entity.", "label": "Long-Term Deposits Term", "terseLabel": "Period of long-term deposit" } } }, "auth_ref": [] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Long-term financial debt - derivatives [Member]", "terseLabel": "Long-term financial debt - derivatives", "verboseLabel": "Derivatives" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnits2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermIncentivePlanInPerformanceUnits2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".", "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]", "terseLabel": "PAGUP 2023" } } }, "auth_ref": [] }, "iva_LongTermSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "LongTermSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term security deposits.", "label": "Long-term security deposits", "terseLabel": "Long-term security deposits" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term borrowings [member]", "terseLabel": "Long-term debt", "verboseLabel": "Long-term" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r352", "r355" ] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Losses on change in fair value of derivatives", "negatedTerseLabel": "Losses on fair value variation" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_LossesOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnDisposalsOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Losses on disposals of non-current assets", "negatedLabel": "Disposals of tangible and intangible fixed assets" } }, "en": { "role": { "documentation": "The losses on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Income tax" } } }, "auth_ref": [] }, "iva_MarkPruzanskiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MarkPruzanskiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Mark Pruzanski.", "label": "Mark Pruzanski [member]", "terseLabel": "Mark Pruzanski" } } }, "auth_ref": [] }, "iva_MarketingAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MarketingAuthorizationMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for when a product implementing one or more inventions receives marketing authorization in one of the stipulated territories.", "label": "Marketing Authorization [Member]", "terseLabel": "Marketing authorization" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity analysis of financial liabilities" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r157", "r278" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r112", "r117", "r118", "r119", "r120", "r122", "r128", "r145", "r159", "r188", "r191", "r195", "r198", "r272", "r314", "r342", "r369" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r112", "r117", "r118", "r119", "r120", "r122", "r128", "r145", "r188", "r191", "r195", "r198", "r272", "r314", "r342", "r369", "r374" ] }, "iva_MaximumAggregateSalesProceedsFromIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumAggregateSalesProceedsFromIssuanceOfShares", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum aggregate sales proceeds under issuance of shares.", "label": "Maximum Aggregate Sales Proceeds From Issuance Of Shares", "terseLabel": "Maximum aggregate sales proceeds" } } }, "auth_ref": [] }, "iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumGrossProceedsReceivableUponExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details" ], "lang": { "en-us": { "role": { "documentation": "The maximum gross proceeds from receivable upon exercise of warrants.", "label": "Maximum Gross Proceeds Receivable upon Exercise of Warrants", "terseLabel": "Maximum gross proceeds" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.", "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants", "terseLabel": "Maximum potential gross proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumPotentialGrossProceedsFromIssuanceOfShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential proceeds from issuance of shares.", "label": "Maximum Potential Gross Proceeds From Issuance Of Shares", "terseLabel": "Aggregate gross proceed" } } }, "auth_ref": [] }, "iva_MaximumProceedsOnExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumProceedsOnExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount of proceeds that may be received on exercise of warrants.", "label": "Maximum Proceeds on Exercise of Warrants", "terseLabel": "Maximum proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_MaximumRoyaltiesPayableToRoyaltyCertificateHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumRoyaltiesPayableToRoyaltyCertificateHolders", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum royalties payable to royalty certificate holders", "label": "Maximum royalties payable to royalty certificate holders", "terseLabel": "Maximum royalties payable to royalty certificate holders" } } }, "auth_ref": [] }, "iva_MaximumShareholdingInEntityToBeLegallyAllowedToParticipateInPlan": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MaximumShareholdingInEntityToBeLegallyAllowedToParticipateInPlan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum shareholding in entity to be legally allowed to participate in plan", "label": "Maximum shareholding in entity to be legally allowed to participate in plan" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r455" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r455" ] }, "iva_MinimumAmountCommittedForFundRaising": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MinimumAmountCommittedForFundRaising", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "The minimum amount committed for borrowing under the agreement.", "label": "Minimum Amount Committed For Fund Raising", "terseLabel": "Minimum amount committed for fund raising" } } }, "auth_ref": [] }, "iva_MinimumGrossFundingToBeRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MinimumGrossFundingToBeRaised", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum gross fund to be raised in fund raising.", "label": "Minimum Gross Funding To Be Raised", "terseLabel": "Minimum gross funding to be raised" } } }, "auth_ref": [] }, "iva_MinimumPeriodToHoldLessThanThresholdValueOfSharesToBecomeEligibleForParticipationInPlan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "MinimumPeriodToHoldLessThanThresholdValueOfSharesToBecomeEligibleForParticipationInPlan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum period to hold less than threshold value of shares to become eligible for participation in plan", "label": "Minimum period to hold less than threshold value of shares to become eligible for participation in plan" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousNoncurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Other non-current assets." } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "negatedTotalLabel": "Total other operating expenses" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "totalLabel": "Total other operating income" } } }, "auth_ref": [ "r535" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r475" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r483" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r456" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssuanceOfSharesAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NetProceedsFromIssuanceOfSharesAndWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds from issuance of shares and warrants.", "label": "Net proceeds from issuance of shares and warrants", "terseLabel": "Net proceeds" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NetProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds from issuing shares", "label": "Net Proceeds From Issuing Shares", "terseLabel": "Net proceeds from issuing shares" } } }, "auth_ref": [] }, "ifrs-full_NetworkInfrastructureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetworkInfrastructureMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Network infrastructure [member]", "terseLabel": "Technical facilities" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing network infrastructure. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "iva_NewBonusShareAwardPlan20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBonusShareAwardPlan20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "New Bonus Share Award Plan 2023-1 [Member]", "terseLabel": "AGA 2023-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20232Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBonusShareAwardPlan20232Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-2).", "label": "AGA 2023-2 [Member]", "terseLabel": "AGA 2023-2" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBonusShareAwardPlanAga20211Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1", "terseLabel": "AGA 2021-1", "verboseLabel": "AGA - Plan 2021 - 1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBonusShareAwardPlanAga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis", "terseLabel": "AGA 2021-bis", "verboseLabel": "AGA - Plan 2021 - bis" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBonusShareAwardPlanAga2021Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021)", "label": "AGA 2021 [Member]", "terseLabel": "AGA 2021" } } }, "auth_ref": [] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis", "terseLabel": "BSA 2019 Bis" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance payments - non-current", "verboseLabel": "Non-current advances to suppliers" } } }, "auth_ref": [] }, "iva_NonCurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentAssetsExcludingDeferredAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-current assets excluding deferred assets", "label": "Non-current assets excluding deferred assets", "totalLabel": "Total non-current assets" } } }, "auth_ref": [] }, "iva_NonCurrentLongTermDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentLongTermDepositsFromCustomers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Non-current portion of non-current borrowings and non-current lease liabilities", "label": "Non-current portion of non-current borrowings and non-current lease liabilities", "terseLabel": "Long-term debt" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of non-current royalty certificates issued.", "label": "Non-current Portion of Non-current Royalty Certificates Issued", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_NonCurrentSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NonCurrentSecurityDeposits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r455" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r418", "r429", "r439", "r463", "r472" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r446" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r445" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r463" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r483" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r483" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r214" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r214" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interest" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r84", "r85", "r310" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r90", "r315", "r356" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities", "verboseLabel": "Longterm contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r108" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Long-term debt - derivatives" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r92", "r316", "r356" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r290", "r319" ] }, "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Non-derivative financial liabilities, undiscounted cash flows", "terseLabel": "Non-derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities." } } }, "auth_ref": [ "r157", "r278" ] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one month [member]", "terseLabel": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r368", "r370", "r376" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r117", "r118", "r128", "r193", "r196", "r313", "r369", "r376" ] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Not later than three months [member]", "terseLabel": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r535" ] }, "iva_NotesToConsolidatedBalanceSheet": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NotesToConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade payables, short-term contract liabilities and other current liabilities" } } }, "auth_ref": [] }, "iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Provisions for retirement benefit obligations" } } }, "auth_ref": [] }, "iva_NotesToInterimCondensedConsolidatedStatementOfIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NotesToInterimCondensedConsolidatedStatementOfIncomeLossAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Basic and diluted loss per share" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "terseLabel": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r535" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional Amount Per Tranche", "terseLabel": "Notional amount per tranche" } } }, "auth_ref": [] }, "iva_NumberOfActiveClinicalSitesInNativ3Trial": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfActiveClinicalSitesInNativ3Trial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of active clinical sites in NATiV3 trial.", "label": "Number of active clinical sites in NATiV3 trial", "terseLabel": "Number of active clinical sites in NATiV3 trial" } } }, "auth_ref": [] }, "iva_NumberOfBonusShareAwardPlansInShareBasedPaymentArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfBonusShareAwardPlansInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of bonus share award plans approved by the reporting entity during the period.", "label": "Number of Bonus Share Award Plans In Share-based Payment Arrangement", "terseLabel": "Number of bonus share award plans" } } }, "auth_ref": [] }, "iva_NumberOfCreditNotesToBeIssuedByCounterpartyInContract": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfCreditNotesToBeIssuedByCounterpartyInContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of credit notes to be issued by counterparty in contract.", "label": "Number of credit notes to be issued by counterparty in contract", "terseLabel": "Number of credit notes to be issued by counterparty in contract" } } }, "auth_ref": [] }, "iva_NumberOfDaysInPhase1TrialOfLanifibranor": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfDaysInPhase1TrialOfLanifibranor", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of days of the Phase I trial of lanifibranor.", "label": "Number of Days in Phase 1 Trial of Lanifibranor", "terseLabel": "Number of days in Phase I trial of Lanifibranor" } } }, "auth_ref": [] }, "iva_NumberOfDevelopmentRegulatoryAndNewMilestonePaymentsInContract": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfDevelopmentRegulatoryAndNewMilestonePaymentsInContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of development, regulatory and new milestone payments in contract.", "label": "Number of development, regulatory and new milestone payments in contract", "terseLabel": "Number of development, regulatory and new milestone payments in contract" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r535" ] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated", "terseLabel": "Number of entities being consolidated" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "iva_NumberOfInstrumentsOtherEquityInstrumentsConverted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfInstrumentsOtherEquityInstrumentsConverted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) converted in a share-based payment arrangement.", "label": "Number Of Instruments Other Equity Instruments, Converted", "negatedLabel": "Converted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of equity instruments granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r140", "r529" ] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Exercised", "negatedTerseLabel": "Vested" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments expired in share-based payment arrangement", "terseLabel": "Number of bonus shares lapsed", "verboseLabel": "Instruments lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited / Lapsed", "verboseLabel": "Number of bonus shares forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance", "terseLabel": "Number of share warrants plan" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r529" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r130", "r133", "r136", "r258", "r261" ] }, "iva_NumberOfParticipantsInPhase1TrialOfLanifibranor": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfParticipantsInPhase1TrialOfLanifibranor", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of participants Phase 1 trial of lanifibranor.", "label": "Number of Participants in Phase I Trial of Lanifibranor", "terseLabel": "Number of participants in Phase I trial of lanifibranor" } } }, "auth_ref": [] }, "iva_NumberOfPatientsRandomizedClinicalTrialMainCohort": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfPatientsRandomizedClinicalTrialMainCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized for main cohort.", "label": "Number of Patients Randomized, Clinical Trial, Main Cohort", "terseLabel": "Number of patients in main cohort" } } }, "auth_ref": [] }, "iva_NumberOfPerformanceObligationsInContract": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfPerformanceObligationsInContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations in contract", "label": "Number of performance obligations in contract", "terseLabel": "Number of performance obligations in contract" } } }, "auth_ref": [] }, "iva_NumberOfPlansOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfPlansOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of plans outstanding", "label": "Number of plans outstanding" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/Lapsed" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r132", "r260" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Number of share options granted", "verboseLabel": "Issued" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r131", "r259" ] }, "iva_NumberOfSharesAcquiredInAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesAcquiredInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired in associate", "label": "Number of shares acquired in associate", "terseLabel": "Number of shares acquired in associate" } } }, "auth_ref": [] }, "iva_NumberOfSharesCallablePerOption": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesCallablePerOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares callable per option", "label": "Number of shares callable per option", "verboseLabel": "Number of shares per SO" } } }, "auth_ref": [] }, "iva_NumberOfSharesCallablePerWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesCallablePerWarrantMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the number of shares callable per warrant used as a measurement input.", "label": "Number of shares callable per warrant [Member]", "terseLabel": "Number of shares callable per warrant" } } }, "auth_ref": [] }, "iva_NumberOfSharesIssuedPerInstrument": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesIssuedPerInstrument", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued per instrument.", "label": "Number Of Shares Issued per Instrument", "terseLabel": "Number of shares per instruments" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of fully authorized, subscribed and paid up shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r201", "r285", "r322" ] }, "iva_NumberOfSharesPerDepositaryReceipt": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesPerDepositaryReceipt", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares per depositary receipt.", "label": "Number of shares per depositary receipt" } } }, "auth_ref": [] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesRepresentedByOneDepositaryReceipt": { "xbrltype": "pureItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesRepresentedByOneDepositaryReceipt", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares represented by one depositary receipt", "terseLabel": "Number of ordinary shares represented by each ADS" } }, "en": { "role": { "documentation": "The number of shares represented by one depositary receipt." } } }, "auth_ref": [ "r535" ] }, "iva_NumberOfSharesSubscribed": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSharesSubscribed", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares subscribed.", "label": "Number Of Shares Subscribed", "terseLabel": "Number of shares subscribed" } } }, "auth_ref": [] }, "iva_NumberOfSubjectsRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfSubjectsRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized.", "label": "Number of Subjects Randomized", "verboseLabel": "Number of patients randomized" } } }, "auth_ref": [] }, "iva_NumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to number of tranches.", "label": "Number Of Tranches", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsExercisedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfWarrantsExercisedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised during the period.", "label": "Number Of Warrants Exercised During Period, Shares", "terseLabel": "Number of warrants exercised during the period" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfWarrantsInEachUnit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants in each unit.", "label": "Number of warrants in each unit" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued", "label": "Number of warrants issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office equipment [member]", "terseLabel": "Office equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r340" ] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage", "verboseLabel": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r543" ] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employee-related expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } } }, "auth_ref": [ "r524" ] }, "iva_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other agreements.", "label": "Other Agreements [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income", "totalLabel": "Total other comprehensive loss" } } }, "auth_ref": [ "r95", "r297", "r326", "r332" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences", "verboseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r317", "r332" ] }, "iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "terseLabel": "Currency translation differences" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit plans", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r317", "r332", "r510" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Items that will be reclassified subsequently to profit or loss", "verboseLabel": "Items that will be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r390", "r391" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Items that will not be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r390", "r391" ] }, "iva_OtherCurrentAndNonCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherCurrentAndNonCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Other current and non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r539" ] }, "iva_OtherCurrentAssetsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherCurrentAssetsAndReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r539" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r381", "r388" ] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance income", "verboseLabel": "Other financial income" } } }, "auth_ref": [ "r535" ] }, "iva_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other financial information" } } }, "auth_ref": [] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Total other income" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "verboseLabel": "Increase / (Decrease) in other non-current financial assets" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r67" ] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "verboseLabel": "Other non-current assets" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "terseLabel": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r539" ] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (loss)" } } }, "auth_ref": [ "r544" ] }, "iva_OtherOperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherOperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other operating income and expenses" } } }, "auth_ref": [] }, "iva_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents other payables.", "label": "Other payables [Member]", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r455" ] }, "iva_OtherPermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherPermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount due to other permanent differences for reconciliation between accounting profit and tax expense income.", "label": "Other Permanent Differences For Reconciliation Between Accounting Profit And Tax Expense Income", "terseLabel": "Other permanent differences" } } }, "auth_ref": [] }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherPropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Other property, plant and equipment [member]", "terseLabel": "Other property, plant and equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r507" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions", "periodEndLabel": "Other provisions at end of period", "periodStartLabel": "Other provisions at beginning of period" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r51", "r242", "r290", "r319" ] }, "ifrs-full_OtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions [abstract]" } } }, "auth_ref": [] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables", "terseLabel": "Other receivables" } } }, "auth_ref": [] }, "iva_OtherShortTermProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "OtherShortTermProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Short term provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance", "terseLabel": "Short-term provisions" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r290", "r319" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r416", "r427", "r437", "r470" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r419", "r430", "r440", "r473" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r419", "r430", "r440", "r473" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value of share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r200", "r284", "r321" ] }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } } }, "auth_ref": [ "r510" ] }, "ifrs-full_PastServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost, defined benefit plans", "negatedLabel": "Past service costs" } } }, "auth_ref": [ "r510" ] }, "iva_PastServiceCreditAssociatedWithImplementationOfRestructuringPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PastServiceCreditAssociatedWithImplementationOfRestructuringPlan", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "documentation": "Past service credit associated with implementation of restructuring plan.", "label": "Past service credit associated with implementation of restructuring plan" } } }, "auth_ref": [] }, "iva_PatentingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PatentingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for when the invention is patented for the first time in one of the territories stipulated in the agreement.", "label": "Patenting [Member]", "terseLabel": "Patenting" } } }, "auth_ref": [] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "iva_PatientsTreatedWithLanifibranorInCombinationWithEmpagliflozinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PatientsTreatedWithLanifibranorInCombinationWithEmpagliflozinMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the member of patients treated with lanifibranor in combination with empagliflozin", "label": "Patients Treated With Lanifibranor in Combination With Empagliflozin [member]", "terseLabel": "Patients treated with lanifibranor in combination with empagliflozin" } } }, "auth_ref": [] }, "iva_PatientsTreatedWithLanifibranorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PatientsTreatedWithLanifibranorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information of patients treated with lanifibranor", "label": "Patients Treated with Lanifibranor [Member]", "terseLabel": "Patients treated with lanifibranor" } } }, "auth_ref": [] }, "iva_PatientsTreatedWithPlaceboMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PatientsTreatedWithPlaceboMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents patients treated with placebo.", "label": "Patients treated with placebo [Member]", "terseLabel": "Patients treated with placebo" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r444" ] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r522" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for share issue costs", "negatedTerseLabel": "Transaction costs related to capital increase", "terseLabel": "Transaction costs related to capital increase" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r522" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r351" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r454" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r454" ] }, "iva_PenaltiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PenaltiesExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties recognized in the period.", "label": "Penalties Expense", "negatedLabel": "Penalties" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r446" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r463" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r456" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r445" ] }, "iva_PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage Of Annual Royalties On Future Sales for Royalty Certificate Holders", "label": "Percentage Of Annual Royalties On Future Sales for Royalty Certificate Holders", "verboseLabel": "Percentage of right annual royalties on future net sales for royalty certificate holders" } } }, "auth_ref": [] }, "iva_PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of dilution subject to regulatory limit for aggregate sales proceeds under issuance of shares.", "label": "Percentage Of Dilution Subject To Regulatory Limit For Aggregate Sales Proceeds", "terseLabel": "Percentage of dilution subject to regulatory limit" } } }, "auth_ref": [] }, "iva_PercentageOfDiscountToVolumeWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfDiscountToVolumeWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to volume weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Volume Weighted Average Trading Price", "terseLabel": "Percentage of discount to volume weighted average trading price of Company's ADS" } } }, "auth_ref": [] }, "iva_PercentageOfLiverTriglycerideReductionAchievedInHigherProportionOfPatients": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfLiverTriglycerideReductionAchievedInHigherProportionOfPatients", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of liver triglyceride reduction achieved in a higher proportion of patients.", "label": "Percentage of liver triglyceride reduction achieved in a higher proportion of patients", "terseLabel": "Percentage of liver triglyceride reduction achieved in a higher proportion of patients" } } }, "auth_ref": [] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsOnCombinationTherapy": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPatientsOnCombinationTherapy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of patients in combination therapy.", "label": "Percentage Of Patients On Combination Therapy", "terseLabel": "Percentage of patients On combination therapy" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsOnLanifibranorAlone": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPatientsOnLanifibranorAlone", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of patients on lanifibranor alone.", "label": "Percentage Of Patients On Lanifibranor Alone", "terseLabel": "Percentage of patients On lanifibranor alone" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsSawTheirHemoglobinLevelsBelowSpecifiedPercentageMentioned": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPatientsSawTheirHemoglobinLevelsBelowSpecifiedPercentageMentioned", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of patients saw their HbA1c levels below specific percentage mentioned.", "label": "Percentage of Patients Saw Their Hemoglobin Levels Below Specified Percentage Mentioned", "terseLabel": "Percentage of patients hemoglobin levels" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsTreatedInTrialShowingSignificantReductionInHepaticFat": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPatientsTreatedInTrialShowingSignificantReductionInHepaticFat", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients treated in trial showing significant reduction in hepatic fat.", "label": "Percentage Of Patients Treated In Trial Showing Significant Reduction In Hepatic Fat", "terseLabel": "Percentage of patients showing significant reduction in hepatic fat" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsWithSignificantFibrosis": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPatientsWithSignificantFibrosis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients with significant fibrosis", "label": "Percentage of patients with significant fibrosis", "terseLabel": "Percentage of patients with significant fibrosis" } } }, "auth_ref": [] }, "iva_PercentageOfPopulationSufferingFromNash": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPopulationSufferingFromNash", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of population suffering from NASH", "label": "Percentage of population suffering from NASH", "terseLabel": "Percentage of population suffering from NASH" } } }, "auth_ref": [] }, "iva_PercentageOfPossibleIncreaseDecreaseInProbabilityOfSuccessOfRegulatoryApproval": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfPossibleIncreaseDecreaseInProbabilityOfSuccessOfRegulatoryApproval", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase (decrease) in the probability of success of regulatory approval used to determine the fair value of the financial instrument.", "label": "Percentage Of possible Increase (Decrease) In Probability Of Success Of Regulatory Approval", "terseLabel": "Change in probability of success" } } }, "auth_ref": [] }, "iva_PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase (decrease) in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Increase (Decrease) In Risk Assumption", "terseLabel": "Percentage of reasonably possible increase (decrease) in risk assumption" } } }, "auth_ref": [] }, "iva_PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible increase or decrease in actuarial assumption", "label": "Percentage of reasonably possible increase or decrease in actuarial assumption" } } }, "auth_ref": [] }, "iva_PercentageOfReductionOfPlaceboGroup": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PercentageOfReductionOfPlaceboGroup", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of reduction in placebo group.", "label": "Percentage Of Reduction Of Placebo Group", "terseLabel": "Percentage of reduction of placebo group" } } }, "auth_ref": [] }, "iva_PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount due to permanent differences for reconciliation between accounting profit and tax expense income.", "label": "Permanent Differences for Reconciliation Between Accounting Profit and Tax Expense Income", "terseLabel": "Permanent differences" } } }, "auth_ref": [] }, "iva_PersonnelCostsAndHeadcount": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PersonnelCostsAndHeadcount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of personnel costs and headcount" } } }, "auth_ref": [] }, "iva_PfwBsaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PfwBsaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents PFW-BSAs.", "label": "PFW BSA [Member]", "terseLabel": "PFW-BSAs" } } }, "auth_ref": [] }, "iva_PgeBpiFrance2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PgeBpiFrance2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE BPI France 2020.", "label": "PGE BPI France 2020 [Member]", "terseLabel": "PGE BPI France 2020" } } }, "auth_ref": [] }, "iva_PgeBpiFrance2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PgeBpiFrance2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE BPI France 2022.", "label": "PGE BPI France 2022 [Member]", "terseLabel": "PGE BPI France 2022" } } }, "auth_ref": [] }, "iva_PgeCa2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PgeCa2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE CA 2020.", "label": "PGE CA 2020 [Member]", "terseLabel": "PGE CA 2020" } } }, "auth_ref": [] }, "iva_PgeLoansPprLoansAndBankOverdraftsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PgeLoansPprLoansAndBankOverdraftsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for PGE (Prt Garanti par l'Etat) loans, PPR (Prts Participatifs Relance) loans and bank overdrafts.", "label": "PGE Loans, the PPR Loans And Bank Overdrafts [Member]", "terseLabel": "PGE loans, the PPR loans; and interests on bank overdrafts" } } }, "auth_ref": [] }, "iva_PgeSg2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PgeSg2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE SG 2020.", "label": "PGE SG 2020 [Member]", "terseLabel": "PGE SG 2020" } } }, "auth_ref": [] }, "iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease", "label": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease [Member]", "terseLabel": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease" } } }, "auth_ref": [] }, "iva_PierreBroquaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PierreBroquaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pierre Broqua", "label": "Pierre Broqua [Member]", "terseLabel": "Pierre Broqua" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r447" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r503" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r446" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss, defined benefit plans", "negatedTotalLabel": "Total" } } }, "auth_ref": [ "r510", "r514" ] }, "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss", "negatedLabel": "Provisions for retirement benefit obligations" } } }, "auth_ref": [ "r514" ] }, "iva_PprCa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PprCa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PPR CA 2022.", "label": "PPR CA 2022 [Member]", "terseLabel": "PPR CA 2022" } } }, "auth_ref": [] }, "iva_PprSg2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PprSg2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PPR SG 2022.", "label": "PPR SG 2022 [Member]", "terseLabel": "PPR SG 2022" } } }, "auth_ref": [] }, "iva_PreFundedWarrantsBsasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PreFundedWarrantsBsasMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for pre-funded warrants - BSAs.", "label": "Pre-funded Warrants BSAs [Member]", "terseLabel": "T2 and T3 BSAs" } } }, "auth_ref": [] }, "ifrs-full_PreviouslyStatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreviouslyStatedMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Previously stated [member]", "terseLabel": "Previously stated" } }, "en": { "role": { "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)." } } }, "auth_ref": [ "r77", "r78", "r79", "r211", "r212", "r213", "r295" ] }, "iva_ProbabilityOfSuccessMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProbabilityOfSuccessMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a probability of success used as a measurement input.", "label": "Probability Of Success, Measurement Input [Member]", "terseLabel": "Probability of success" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r522" ] }, "iva_ProceedsFromIssuanceOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProceedsFromIssuanceOfRoyaltyCertificates", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of royalty certificates.", "label": "Proceeds from Issuance of Royalty Certificates", "terseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "iva_ProceedsFromIssuanceOfSharesAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProceedsFromIssuanceOfSharesAndWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of shares and warrants.", "label": "Proceeds from issuance of shares and warrants", "terseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase", "verboseLabel": "Proceeds from issuance of shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r348" ] }, "iva_ProceedsFromLicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProceedsFromLicensingArrangements", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements.", "label": "Proceeds From Licensing Arrangements", "terseLabel": "Amount received on licensing arrangements" } } }, "auth_ref": [] }, "iva_ProceedsFromLicensingArrangementsAfterDeductionOfWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProceedsFromLicensingArrangementsAfterDeductionOfWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements after deduction of withholding taxes", "label": "Proceeds From Licensing Arrangements after Deduction of Withholding Taxes", "terseLabel": "Amount received on licensing arrangements after deduction of withholding taxes" } } }, "auth_ref": [] }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r181", "r362", "r378" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r181", "r362", "r378" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "negatedLabel": "Net loss for the period", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r81", "r83", "r174", "r177", "r238", "r257", "r296", "r325", "r356", "r364" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit (loss)", "verboseLabel": "Net operating loss" } } }, "auth_ref": [ "r343", "r544" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment including right-of-use assets", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r114", "r509", "r538" ] }, "iva_PropertyPlantAndEquipmentUsedInResearchAndDevelopmentActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PropertyPlantAndEquipmentUsedInResearchAndDevelopmentActivitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents property, plant and equipment used in research and development activities.", "label": "Property, plant and equipment used in research and development activities [member]", "terseLabel": "Property, plant and equipment used in research and development activities" } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Group's share in %", "verboseLabel": "Proportion of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r38", "r40", "r88" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r38", "r40", "r86" ] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Provision used, other provisions", "negatedLabel": "Reversals used" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r53", "r244" ] }, "iva_ProvisionsRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ProvisionsRestructuring", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for restructuring.", "label": "Provisions - Restructuring", "negatedLabel": "Provisions - Restructuring" } } }, "auth_ref": [] }, "iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of interests in investments accounted for using equity method, price per share", "label": "Purchase of interests in investments accounted for using equity method, price per share", "terseLabel": "Purchase of interests in investments accounted for using equity method, price per share" } } }, "auth_ref": [] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "iva_PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage amount of operating expenses that were paid in a currency other than the reporting currency.", "label": "Purchases In Foreign Currency As A Percentage Of Operating Expenses", "terseLabel": "Foreign currency expenses as a percentage of operating expenses" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r444" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r444" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r107", "r122", "r136", "r207", "r359", "r361", "r530" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r73", "r107", "r122", "r136", "r207", "r359", "r361", "r530" ] }, "iva_ReceiptOfPaymentsUnderLicensingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ReceiptOfPaymentsUnderLicensingArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for receipt of payments under Licensing arrangements.", "label": "Receipt Of Payments Under Licensing Arrangements [Member]", "terseLabel": "Receipt of payments under Licensing arrangements" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "terseLabel": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]", "terseLabel": "Reconciliation of changes in property, plant and equipment" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r411", "r422", "r432", "r465" ] }, "iva_ReferencePricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ReferencePricePerUnit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Reference price per unit", "label": "Reference price per unit", "terseLabel": "Reference price" } } }, "auth_ref": [] }, "iva_RegisteredUnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RegisteredUnderwrittenPublicOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for registered underwritten public offering.", "label": "Registered Underwritten Public Offering [Member]", "terseLabel": "Registered underwritten public offering" } } }, "auth_ref": [] }, "iva_RegulatoryLimitForDilutionRollingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RegulatoryLimitForDilutionRollingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The rolling period for regulatory limit of dilution under the sale of stock.", "label": "Regulatory Limit for Dilution, Rolling Period", "terseLabel": "Rolling period" } } }, "auth_ref": [] }, "iva_RemainingAmountPayableUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RemainingAmountPayableUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Remaining amount payable under contract.", "label": "Remaining amount payable under contract" } } }, "auth_ref": [] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } } }, "auth_ref": [ "r544" ] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } } }, "auth_ref": [ "r59", "r250" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r27", "r231" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r27", "r231", "r385" ] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r77", "r78", "r79", "r121", "r211", "r212", "r213", "r295", "r537" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r412", "r423", "r433", "r466" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r413", "r424", "r434", "r467" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r420", "r431", "r441", "r474" ] }, "iva_RestructuringAndRelatedCostsPlannedWorkforceReduction": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RestructuringAndRelatedCostsPlannedWorkforceReduction", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related costs, planned workforce reduction.", "label": "Restructuring and related costs, planned workforce reduction" } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvision", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring provision", "terseLabel": "Amount of provision for restructuring" } }, "en": { "role": { "documentation": "The amount of provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_RestructuringProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvisionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring provision [member]", "terseLabel": "Restructuring provision" } }, "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Retained earnings, excluding profit (loss) for reporting period", "verboseLabel": "earnings brought forward" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r541" ] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves (Accumulated losses)" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r541" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r534" ] }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r77", "r78", "r79", "r211", "r212", "r213", "r295" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "totalLabel": "Total revenues" } } }, "auth_ref": [ "r94", "r143", "r171", "r176", "r181", "r182", "r184", "r328", "r356", "r383", "r384" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenues and other income" } } }, "auth_ref": [ "r544" ] }, "iva_RevenueAndOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RevenueAndOtherIncomeAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenues and other income" } } }, "auth_ref": [] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenues and other income" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "auth_ref": [ "r109", "r110", "r189" ] }, "iva_ReversalOfProvisionsForInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ReversalOfProvisionsForInventory", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reversals of provisions for the cost of inventory.", "label": "Reversal Of Provisions For Inventory", "terseLabel": "Use of provisions - Inventory" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets [member]", "terseLabel": "Right of use" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r113" ] }, "iva_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate of other equity instruments granted.", "label": "Risk-Free Interest Rate, Other Equity Instruments Granted", "terseLabel": "Risk-free rate" } } }, "auth_ref": [] }, "iva_RoyaltiesOnCommercialSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltiesOnCommercialSalesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalties on commercial sales.", "label": "Royalties on commercial sales" } } }, "auth_ref": [] }, "iva_RoyaltyCertificateLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificateLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Royalty Certificate Liabilities.", "label": "Royalty Certificate Liabilities [Member]", "terseLabel": "Royalty Certificate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificates2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificates2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to royalty certificates 2023.", "label": "Royalty Certificates 2023 [Member]", "terseLabel": "2023 Royalty Certificates" } } }, "auth_ref": [] }, "iva_RoyaltyCertificates2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificates2024Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates 2024.", "label": "Royalty Certificates 2024 [Member]", "terseLabel": "2024 Royalty Certificates" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificatesEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate on royalty certificates.", "label": "Royalty Certificates, Effective Interest Rate", "terseLabel": "Royalty certificates, effective interest rate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificatesLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates liabilities.", "label": "Royalty Certificates Liabilities [Member]", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for Royalty Certificates liabilities.", "label": "Royalty Certificates Liabilities Policy [Policy Text Block]", "terseLabel": "Royalty Certificates liabilities" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "RoyaltyCertificatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to royalty certificates.", "label": "Royalty Certificates [Member]", "verboseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r483" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r483" ] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } } }, "auth_ref": [ "r544" ] }, "iva_SamsaraBioCapitalL.pMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SamsaraBioCapitalL.pMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Samsara BioCapital L.P.", "label": "Samsara Bio Capital L.p [Member]", "terseLabel": "Samsara Bio Capital L.p" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": [] }, "iva_ScenarioOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScenarioOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario one.", "label": "Scenario One [Member]", "terseLabel": "First tranche" } } }, "auth_ref": [] }, "iva_ScenarioThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScenarioThreeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario three.", "label": "Scenario Three [Member]", "verboseLabel": "Scenario Three" } } }, "auth_ref": [] }, "iva_ScenarioTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScenarioTwoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario two.", "label": "Scenario Two [Member]", "terseLabel": "Second tranche" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScheduleOfInventoryDisclosureLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]", "terseLabel": "Inventories" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScheduleOfInventoryDisclosureTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "auth_ref": [] }, "iva_ScheduleOfValuationApproachForAbsaStructuredFinancingArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ScheduleOfValuationApproachForAbsaStructuredFinancingArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation approach for ABSAs structured financing arrangement.", "label": "Schedule Of Valuation Approach For ABSA Structured Financing Arrangement [Table Text Block]", "terseLabel": "Schedule of assumptions and results" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r393" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r395" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Sensitivity analysis for types of market risk [text block]", "terseLabel": "Schedule of sensitivity analysis of the company's assets" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r158" ] }, "iva_ServiceContractWithAvantSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ServiceContractWithAvantSanteMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for service contract with Avant Sante.", "label": "Service contract with Avant Sante [Member]", "terseLabel": "Service contract with Avant Sante" } } }, "auth_ref": [] }, "iva_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ServiceProvidersMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers", "terseLabel": "Service providers" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs", "verboseLabel": "Transaction costs" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax", "terseLabel": "Currency translation differences - equity method" } }, "en": { "role": { "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of profit (loss) of associates accounted for using equity method", "totalLabel": "Share of net profit (loss) - Equity method" } } }, "auth_ref": [ "r544" ] }, "iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Share of profit (loss) of associates accounted for using equity method before eliminations", "label": "Share of profit (loss) of associates accounted for using equity method before eliminations", "terseLabel": "Share of net loss" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAbstract", "lang": { "en-us": { "role": { "label": "Share of net profit (loss) - Equity method" } } }, "auth_ref": [] }, "iva_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethod" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments {Text Block]", "terseLabel": "Share of net profit (loss) - Equity method" } } }, "auth_ref": [] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share options [member]", "terseLabel": "Stock options" } }, "en": { "role": { "documentation": "This member stands for share options." } } }, "auth_ref": [ "r517" ] }, "iva_SharePerUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SharePerUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value per unit of shares.", "label": "Share, Per Unit fair Value", "terseLabel": "Unit fair value" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r382", "r389" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r300" ] }, "iva_SharePriceMeasurementInput": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SharePriceMeasurementInput", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Share price, measurement input.", "label": "Share price, measurement input" } } }, "auth_ref": [] }, "iva_SharesAndPrefundedWarrantsAccumulatedSubscriptionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SharesAndPrefundedWarrantsAccumulatedSubscriptionPrice", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares and prefunded warrants, accumulated subscription price.", "label": "Shares and prefunded warrants, accumulated subscription price", "terseLabel": "Subscription price of shares and prefunded warrants" } } }, "auth_ref": [] }, "iva_SharesMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SharesMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of shares used to calculate fair value of shares.", "label": "Shares, Maturity Term", "terseLabel": "Maturity" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "iva_ShortTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ShortTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term financial debt, derivatives.", "label": "Short Term Financial Debt Derivatives [Member]", "terseLabel": "Shortterm financial debt - derivatives" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term borrowings [member]", "terseLabel": "Short-term debt", "verboseLabel": "Short-term" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r352", "r355" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r526" ] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Short-term deposit accounts" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_ShorttermRestructuringProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermRestructuringProvision", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current restructuring provision" } }, "en": { "role": { "documentation": "The amount of current provision for restructuring. [Refer: Restructuring provision]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39", "r41", "r102", "r280" ] }, "ifrs-full_SignificantInvestmentsInAssociatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationOrdinarySharesOfHepalysDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitLossEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Associates [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r39", "r41", "r102", "r280" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39", "r41", "r101", "r279" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r39", "r41", "r101", "r279" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input, liabilities", "terseLabel": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Social security contributions", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [ "r516" ] }, "iva_SocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SocieteGeneraleMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Societe Generale.", "label": "Societe Generale" } } }, "auth_ref": [] }, "iva_SpecificPercentageOfHemoglobinLevel": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SpecificPercentageOfHemoglobinLevel", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the specific percentage of Hemoglobin levels presented.", "label": "Specific Percentage of Hemoglobin Level", "terseLabel": "Specific percentage of hemoglobin level" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated statement of changes in shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Consolidated statement of changes in shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfCashFlowsParenthetical", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r300" ] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated statement of comprehensive income (loss)" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated statement of financial position" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r415", "r426", "r436", "r469" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodSharesWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockIssuedDuringPeriodSharesWarrantExercised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during period upon exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrant Exercised", "terseLabel": "Shares issued during period upon exercise of warrants" } } }, "auth_ref": [] }, "iva_StockOptionUnitValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionUnitValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock option unit value", "label": "Stock option unit value" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionsPlan20241Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2024-1'.", "label": "Stock Options Plan 2024-1 [Member]", "terseLabel": "SO 2024-1" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionsPlan20242Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2024-2'.", "label": "Stock Options Plan 2024-2 [Member]", "terseLabel": "SO 2024-2" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionsPlan20251Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-1'.", "label": "Stock Options Plan 2025-1 [Member]", "terseLabel": "SO 2025-1" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionsPlan20252Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-2'.", "label": "Stock Options Plan 2025-2 [Member]", "terseLabel": "SO 2025-2" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "StockOptionsPlan20253Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-3'.", "label": "Stock Options Plan 2025-3 [Member]", "terseLabel": "SO 2025-3" } } }, "auth_ref": [] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "iva_SubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SubscriptionPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share in new issue of shares", "label": "Subscription Price Per Share", "terseLabel": "Subscription price" } } }, "auth_ref": [] }, "iva_SubscriptionPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SubscriptionPricePerUnit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per unit.", "label": "Subscription price per unit" } } }, "auth_ref": [] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "iva_SupplierFisherClinicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SupplierFisherClinicalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for supplier Fisher Clinical.", "label": "Supplier Fisher Clinical [Member]", "terseLabel": "Supplier Fisher Clinical" } } }, "auth_ref": [] }, "iva_SupplierMarkenSasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SupplierMarkenSasMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for supplier Marken SAS.", "label": "Supplier Marken SAS [Member]", "terseLabel": "Supplier Marken SAS" } } }, "auth_ref": [] }, "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "iva_T1BisBsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T1BisBsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T1 bis BSA warrants.", "label": "T1 bis BSA Warrants [Member]", "terseLabel": "T1 bis BSA Warrants" } } }, "auth_ref": [] }, "iva_T1BisSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T1BisSharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T1 bis Shares.", "label": "T1 BIS Shares [Member]", "terseLabel": "T1 bis Shares" } } }, "auth_ref": [] }, "iva_T1BsaWarrantsAndT1BisBsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T1BsaWarrantsAndT1BisBsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents T1 BSA warrants and T1 bis BSA warrants.", "label": "T1 BSA warrants and T1 bis BSA warrants [Member]", "terseLabel": "T1 BSA warrants and T1 bis BSA warrants" } } }, "auth_ref": [] }, "iva_T1BsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T1BsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T1 BSA warrants.", "label": "T1 BSA Warrants [Member]", "terseLabel": "T1 BSA Warrants" } } }, "auth_ref": [] }, "iva_T1NewShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T1NewShareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to T1 new shares.", "label": "T1 New Share [Member]", "terseLabel": "T1 New Share" } } }, "auth_ref": [] }, "iva_T2BsaCallOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2BsaCallOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 BSA call option.", "label": "T2 BSA Call options [Member]", "terseLabel": "T2 BSA Call options" } } }, "auth_ref": [] }, "iva_T2BsaPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2BsaPrefundedWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 BSA pre-funded warrants.", "label": "T2 BSA Prefunded Warrants [Member]", "terseLabel": "T2 BSA Prefunded Warrants" } } }, "auth_ref": [] }, "iva_T2NewShareAndT3BsasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2NewShareAndT3BsasMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 new shares and T3 BSAs.", "label": "T2 New Share And T3 BSAs [Member]", "terseLabel": "ABSAs" } } }, "auth_ref": [] }, "iva_T2NewShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2NewShareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 New Share.", "label": "T2 New Share [Member]", "terseLabel": "T2 New Share" } } }, "auth_ref": [] }, "iva_T2NewSharesAndT2BsasCallOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2NewSharesAndT2BsasCallOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesMovementsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 New Shares and T2 BSAs call options.", "label": "T2 New Shares and T2 BSAs Call Options [Member]", "terseLabel": "T2 New Shares and T2 BSAs call options", "verboseLabel": "T2 New Shares and T2 BSAs" } } }, "auth_ref": [] }, "iva_T2NewSharesCallOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T2NewSharesCallOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 New Shares call option.", "label": "T2 New Shares Call options [Member]", "terseLabel": "T2 New Shares Call options" } } }, "auth_ref": [] }, "iva_T3BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T3BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to T3 BSA share warrant.", "label": "T3 Bsa Share Warrants [Member]" } } }, "auth_ref": [] }, "iva_T3BsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T3BsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T3 BSA warrants.", "label": "T3 BSA Warrants [Member]", "verboseLabel": "T3 BSA warrants" } } }, "auth_ref": [] }, "iva_T3BsasWarrantsAttachedToT2BsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T3BsasWarrantsAttachedToT2BsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T3 BSA warrants attached to T2 BSA warrants.", "label": "T3 BSAs Warrants Attached To T2 BSA Warrants [Member]", "terseLabel": "T3 BSAs Warrants Attached To T2 BSA Warrants" } } }, "auth_ref": [] }, "iva_T3BsasWarrantsAttachedToT2NewSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "T3BsasWarrantsAttachedToT2NewSharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T3 BSA warrants attached to T2 new shares.", "label": "T3 BSAs Warrants Attached To T2 New Shares [Member]", "terseLabel": "T3 BSAs Warrants Attached To T2 New Shares" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r462" ] }, "iva_TaxEffectImpairmentLossOfDeferredTaxAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TaxEffectImpairmentLossOfDeferredTaxAsset", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to impairment loss of deferred tax asset.", "label": "Tax Effect, Impairment loss Of Deferred Tax Asset", "negatedLabel": "Impairment loss of deferred tax asset" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedLabel": "Tax rate differences" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r216" ] }, "iva_TaxEffectOfTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TaxEffectOfTaxCredits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to tax effect of tax credits.", "label": "Tax effect of tax credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "iva_TaxEffectOfTemporaryDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TaxEffectOfTemporaryDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to temporary differences.", "label": "Tax Effect Of Temporary Differences For Reconciliation Between Accounting Profit And Tax Expense Income", "terseLabel": "Temporary differences" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Tax benefit at theoretical rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r216" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8", "r221" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r8", "r221" ] }, "iva_TermOfRoyaltyCertificate": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TermOfRoyaltyCertificate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of royalty certificate in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term Of Royalty Certificate", "terseLabel": "Term of royalty certificate" } } }, "auth_ref": [] }, "iva_ThresholdNumberOfTradingDaysOfVolumeWeightedAveragePriceTakenForSubscriptionPriceCalculation": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "ThresholdNumberOfTradingDaysOfVolumeWeightedAveragePriceTakenForSubscriptionPriceCalculation", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of trading days of volume weighted average price of ordinary shares taken for the calculation of subscription price of share.", "label": "Threshold Number Of Trading Days Of Volume Weighted Average Price Taken For Subscription Price Calculation", "terseLabel": "Number of trading days of volume weighted average price" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicensingAgreementWithHepalysDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r73", "r107", "r122", "r136", "r207", "r359", "r361", "r530" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r454" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r461" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r387", "r542" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade receivables and others" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r289", "r306", "r318" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]", "terseLabel": "Other current and non-current liabilities", "verboseLabel": "Trade payables and short-term contract liabilities" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndShortTermContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradePayablesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade payables and short-term contract liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables [Member]", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r150", "r154", "r273", "r276", "r366", "r535" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r482" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r484" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "iva_TransactionCostsOnIssueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TransactionCostsOnIssueOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction costs on issue of warrants", "label": "Transaction costs on issue of warrants", "terseLabel": "Transaction costs on issue of warrants" } } }, "auth_ref": [] }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Transaction price allocated to remaining performance obligations", "terseLabel": "Aggregate constrained transaction price" } }, "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]]" } } }, "auth_ref": [ "r111", "r190" ] }, "iva_TransactionsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TransactionsCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred during the period.", "label": "Transactions Costs", "negatedLabel": "Transaction costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "iva_TransferOfKnowHowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TransferOfKnowHowMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The member represents transfer of know-how.", "label": "Transfer of know-how [Member]", "terseLabel": "Transfer of know-how" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r485" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r486" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r486" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r484" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r484" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r487" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r485" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury Shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r42", "r382", "r389" ] }, "iva_TreatmentPeriodUnderStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "TreatmentPeriodUnderStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompanyToPresentResultsOfLegendPhaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details" ], "lang": { "en-us": { "role": { "documentation": "Treatment period under study", "label": "Treatment period under study", "terseLabel": "Treatment period under study" } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28", "r123", "r124", "r125", "r127", "r144", "r148", "r149", "r232" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementInflationRiskDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r28", "r123", "r124", "r125", "r127", "r144", "r148", "r149", "r232" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r137", "r263" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsAndStockOptionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r137", "r263" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "verboseLabel": "USA" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "auth_ref": [] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r535" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r535" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r481" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105", "r528" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r105", "r528" ] }, "ifrs-full_UnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxCreditsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax credits [member]", "terseLabel": "Tax credits" } }, "en": { "role": { "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r8", "r221" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "terseLabel": "Unrecognized Deferred tax assets" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r5", "r218" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses [member]", "terseLabel": "Tax losses" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r8", "r221" ] }, "iva_UpsizedUnderwrittenPublicOfferingIncludingUnderwritersOptionsAtMarketProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "UpsizedUnderwrittenPublicOfferingIncludingUnderwritersOptionsAtMarketProgramMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsBalanceFromStatementOfCashFlowsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to upsized underwritten public offering including underwriters' options pursuant to At-The-Market Program.", "label": "Upsized Underwritten Public Offering Including Underwriters' Options, At the Market Program [Member]", "terseLabel": "Upsized underwritten public offering including underwriters' options, at the market program" } } }, "auth_ref": [] }, "iva_UsedProvisionsReversedOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "UsedProvisionsReversedOtherShortTermProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Used provisions reversed, other short term provisions.", "label": "Used provisions reversed, other short term provisions", "negatedLabel": "Reversals used" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Useful lives of property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r10", "r222" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r450" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } } }, "auth_ref": [ "r516" ] }, "iva_WarrantAgreementWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantAgreementWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.", "label": "Warrant Agreement With The European Investment Bank [Member]", "terseLabel": "Warrant agreement with the European Investment Bank" } } }, "auth_ref": [] }, "iva_WarrantAverageLife": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantAverageLife", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrant.", "label": "Warrant Average Life", "verboseLabel": "Maturity (months)" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsCapOfPutOption", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (k\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsExercisableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsExercisableTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of warrants exercisable.", "label": "Warrants Exercisable Term", "terseLabel": "Warrants exercisable term" } } }, "auth_ref": [] }, "iva_WarrantsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsRiskFreeInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate used to calculate fair value of warrants.", "label": "Warrants, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "terseLabel": "Subscription premium price per share (\u20ac)", "verboseLabel": "Subscription price per warrant" } } }, "auth_ref": [] }, "iva_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsOf2025Details" ], "lang": { "en-us": { "role": { "documentation": "Term of warrants.", "label": "Warrants Term", "terseLabel": "Term of warrants" } } }, "auth_ref": [] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesShortTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value per unit of warrants outstanding.", "label": "Warrants, Unit Fair Value", "verboseLabel": "Unit Fair value (\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r529" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDerivativesAndRoyaltyCertificatesLiabilitiesDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)", "verboseLabel": "Exercise price (\u20ac)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r529" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspcePlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityPerformanceUnitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Fair value per instrument at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Fair value per SO at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r135" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r45" ] }, "iva_WithHoldingTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WithHoldingTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the percentage of withholding tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets.", "label": "With Holding Tax Rate", "terseLabel": "Withholding tax (as a percent)" } } }, "auth_ref": [] }, "iva_WithholdingTaxExpenseIncomeRecognizedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20251231", "localname": "WithholdingTaxExpenseIncomeRecognizedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of withholding tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets.", "label": "Withholding Tax Expense Income Recognized In Profit Or Loss", "terseLabel": "Withholding taxes" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r448" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_e&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B14", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20B&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_d&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "179", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "210", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_210&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_a&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_b&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56A&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_b&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_a&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_d&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard", "URIDate": "2025-03-27" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard", "URIDate": "2025-03-27" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard", "URIDate": "2025-03-27" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_20_d&doctype=Standard", "URIDate": "2025-03-27" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }